Carcinoma: A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm but is often wrongly used as a synonym for "cancer." (From Dorland, 27th ed)Carcinoma, Squamous Cell: A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.Carcinoma in Situ: A lesion with cytological characteristics associated with invasive carcinoma but the tumor cells are confined to the epithelium of origin, without invasion of the basement membrane.Carcinoma, Papillary: A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)Liver Neoplasms: Tumors or cancer of the LIVER.Carcinoma, Ductal, Breast: An invasive (infiltrating) CARCINOMA of the mammary ductal system (MAMMARY GLANDS) in the human BREAST.Carcinoma, Basal Cell: A malignant skin neoplasm that seldom metastasizes but has potentialities for local invasion and destruction. Clinically it is divided into types: nodular, cicatricial, morphaic, and erythematoid (pagetoid). They develop on hair-bearing skin, most commonly on sun-exposed areas. Approximately 85% are found on the head and neck area and the remaining 15% on the trunk and limbs. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1471)Immunohistochemistry: Histochemical localization of immunoreactive substances using labeled antibodies as reagents.Carcinoma, Transitional Cell: A malignant neoplasm derived from TRANSITIONAL EPITHELIAL CELLS, occurring chiefly in the URINARY BLADDER; URETERS; or RENAL PELVIS.Carcinoma, Bronchogenic: Malignant neoplasm arising from the epithelium of the BRONCHI. It represents a large group of epithelial lung malignancies which can be divided into two clinical groups: SMALL CELL LUNG CANCER and NON-SMALL-CELL LUNG CARCINOMA.Carcinoma, Intraductal, Noninfiltrating: A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.Carcinoma, Adenoid Cystic: Carcinoma characterized by bands or cylinders of hyalinized or mucinous stroma separating or surrounded by nests or cords of small epithelial cells. When the cylinders occur within masses of epithelial cells, they give the tissue a perforated, sievelike, or cribriform appearance. Such tumors occur in the mammary glands, the mucous glands of the upper and lower respiratory tract, and the salivary glands. They are malignant but slow-growing, and tend to spread locally via the nerves. (Dorland, 27th ed)Carcinoma, Small Cell: An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)Tumor Markers, Biological: Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or body fluids. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including hormones, antigens, amino and nucleic acids, enzymes, polyamines, and specific cell membrane proteins and lipids.Carcinoma, Medullary: A carcinoma composed mainly of epithelial elements with little or no stroma. Medullary carcinomas of the breast constitute 5%-7% of all mammary carcinomas; medullary carcinomas of the thyroid comprise 3%-10% of all thyroid malignancies. (From Dorland, 27th ed; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1141; Segen, Dictionary of Modern Medicine, 1992)Adenocarcinoma: A malignant epithelial tumor with a glandular organization.Carcinoma, Lobular: A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)Carcinoma, Neuroendocrine: A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)Neoplasm Invasiveness: Ability of neoplasms to infiltrate and actively destroy surrounding tissue.Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.Cell Line, Tumor: A cell line derived from cultured tumor cells.Prognosis: A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations.Thyroid Neoplasms: Tumors or cancer of the THYROID GLAND.Breast Neoplasms: Tumors or cancer of the human BREAST.Neoplasm Staging: Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.Gene Expression Regulation, Neoplastic: Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue.Tumor Cells, Cultured: Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely.Lung Neoplasms: Tumors or cancer of the LUNG.Carcinoma, Mucoepidermoid: A tumor of both low- and high-grade malignancy. The low-grade grow slowly, appear in any age group, and are readily cured by excision. The high-grade behave aggressively, widely infiltrate the salivary gland and produce lymph node and distant metastases. Mucoepidermoid carcinomas account for about 21% of the malignant tumors of the parotid gland and 10% of the sublingual gland. They are the most common malignant tumor of the parotid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575; Holland et al., Cancer Medicine, 3d ed, p1240)Carcinoma, Adenosquamous: A mixed adenocarcinoma and squamous cell or epidermoid carcinoma.Carcinoma, Endometrioid: An adenocarcinoma characterized by the presence of cells resembling the glandular cells of the ENDOMETRIUM. It is a common histological type of ovarian CARCINOMA and ENDOMETRIAL CARCINOMA. There is a high frequency of co-occurrence of this form of adenocarcinoma in both tissues.Head and Neck Neoplasms: Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651)Carcinoma, Embryonal: A highly malignant, primitive form of carcinoma, probably of germinal cell or teratomatous derivation, usually arising in a gonad and rarely in other sites. It is rare in the female ovary, but in the male it accounts for 20% of all testicular tumors. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, p1595)Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.Mouth Neoplasms: Tumors or cancer of the MOUTH.Carcinoma, Merkel Cell: A carcinoma arising from MERKEL CELLS located in the basal layer of the epidermis and occurring most commonly as a primary neuroendocrine carcinoma of the skin. Merkel cells are tactile cells of neuroectodermal origin and histologically show neurosecretory granules. The skin of the head and neck are a common site of Merkel cell carcinoma, occurring generally in elderly patients. (Holland et al., Cancer Medicine, 3d ed, p1245)Carcinoma, Ductal: Malignant neoplasms involving the ductal systems of any of a number of organs, such as the MAMMARY GLANDS, the PANCREAS, the PROSTATE, or the LACRIMAL GLAND.Lymphatic Metastasis: Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system.Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.Adrenocortical Carcinoma: A malignant neoplasm of the ADRENAL CORTEX. Adrenocortical carcinomas are unencapsulated anaplastic (ANAPLASIA) masses sometimes exceeding 20 cm or 200 g. They are more likely to be functional than nonfunctional, and produce ADRENAL CORTEX HORMONES that may result in hypercortisolism (CUSHING SYNDROME); HYPERALDOSTERONISM; and/or VIRILISM.Colonic Neoplasms: Tumors or cancer of the COLON.Carcinoma, Verrucous: A variant of well-differentiated epidermoid carcinoma that is most common in the oral cavity, but also occurs in the larynx, nasal cavity, esophagus, penis, anorectal region, vulva, vagina, uterine cervix, and skin, especially on the sole of the foot. Most intraoral cases occur in elderly male abusers of smokeless tobacco. The treatment is surgical resection. Radiotherapy is not indicated, as up to 30% treated with radiation become highly aggressive within six months. (Segen, Dictionary of Modern Medicine, 1992)Carcinoma, Signet Ring Cell: A poorly differentiated adenocarcinoma in which the nucleus is pressed to one side by a cytoplasmic droplet of mucus. It usually arises in the gastrointestinal system.Neoplasm Metastasis: The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.Urinary Bladder Neoplasms: Tumors or cancer of the URINARY BLADDER.Stomach Neoplasms: Tumors or cancer of the STOMACH.Neoplasm Proteins: Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.Skin Neoplasms: Tumors or cancer of the SKIN.Neoplasm Recurrence, Local: The local recurrence of a neoplasm following treatment. It arises from microscopic cells of the original neoplasm that have escaped therapeutic intervention and later become clinically visible at the original site.Mice, Nude: Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses.Carcinoma, Large Cell: A tumor of undifferentiated (anaplastic) cells of large size. It is usually bronchogenic. (From Dorland, 27th ed)DNA, Neoplasm: DNA present in neoplastic tissue.Laryngeal Neoplasms: Cancers or tumors of the LARYNX or any of its parts: the GLOTTIS; EPIGLOTTIS; LARYNGEAL CARTILAGES; LARYNGEAL MUSCLES; and VOCAL CORDS.Antineoplastic Agents: Substances that inhibit or prevent the proliferation of NEOPLASMS.Retrospective Studies: Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.Uterine Cervical Neoplasms: Tumors or cancer of the UTERINE CERVIX.Immunoenzyme Techniques: Immunologic techniques based on the use of: (1) enzyme-antibody conjugates; (2) enzyme-antigen conjugates; (3) antienzyme antibody followed by its homologous enzyme; or (4) enzyme-antienzyme complexes. These are used histologically for visualizing or labeling tissue specimens.RNA, Messenger: RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm.Neoplasm Transplantation: Experimental transplantation of neoplasms in laboratory animals for research purposes.Neoplasms, Multiple Primary: Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.Survival Rate: The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.Adenocarcinoma, Follicular: An adenocarcinoma of the thyroid gland, in which the cells are arranged in the form of follicles. (From Dorland, 27th ed)Survival Analysis: A class of statistical procedures for estimating the survival function (function of time, starting with a population 100% well at a given time and providing the percentage of the population still well at later times). The survival analysis is then used for making inferences about the effects of treatments, prognostic factors, exposures, and other covariates on the function.Adenocarcinoma, Mucinous: An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)Treatment Outcome: Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.Antigens, Neoplasm: Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.Embryonal Carcinoma Stem Cells: The malignant stem cells of TERATOCARCINOMAS, which resemble pluripotent stem cells of the BLASTOCYST INNER CELL MASS. The EC cells can be grown in vitro, and experimentally induced to differentiate. They are used as a model system for studying early embryonic cell differentiation.Reverse Transcriptase Polymerase Chain Reaction: A variation of the PCR technique in which cDNA is made from RNA via reverse transcription. The resultant cDNA is then amplified using standard PCR protocols.Precancerous Conditions: Pathological processes that tend eventually to become malignant. (From Dorland, 27th ed)Carcinoma, Papillary, Follicular: A thyroid neoplasm of mixed papillary and follicular arrangement. Its biological behavior and prognosis is the same as that of a papillary adenocarcinoma of the thyroid. (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1271)Gallbladder Neoplasms: Tumors or cancer of the gallbladder.Carcinoma, Non-Small-Cell Lung: A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.Tumor Suppressor Protein p53: Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER.Endometrial Neoplasms: Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.Adenocarcinoma, Clear Cell: An adenocarcinoma characterized by the presence of varying combinations of clear and hobnail-shaped tumor cells. There are three predominant patterns described as tubulocystic, solid, and papillary. These tumors, usually located in the female reproductive organs, have been seen more frequently in young women since 1970 as a result of the association with intrauterine exposure to diethylstilbestrol. (From Holland et al., Cancer Medicine, 3d ed)Disease Progression: The worsening of a disease over time. This concept is most often used for chronic and incurable diseases where the stage of the disease is an important determinant of therapy and prognosis.Colorectal Neoplasms: Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.Cell Proliferation: All of the processes involved in increasing CELL NUMBER including CELL DIVISION.alpha-Fetoproteins: The first alpha-globulins to appear in mammalian sera during FETAL DEVELOPMENT and the dominant serum proteins in early embryonic life.Tongue Neoplasms: Tumors or cancer of the TONGUE.Apoptosis: One of the mechanisms by which CELL DEATH occurs (compare with NECROSIS and AUTOPHAGOCYTOSIS). Apoptosis is the mechanism responsible for the physiological deletion of cells and appears to be intrinsically programmed. It is characterized by distinctive morphologic changes in the nucleus and cytoplasm, chromatin cleavage at regularly spaced sites, and the endonucleolytic cleavage of genomic DNA; (DNA FRAGMENTATION); at internucleosomal sites. This mode of cell death serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth.Pancreatic Neoplasms: Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).Cystadenocarcinoma, Serous: A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)Carcinoma, Lewis Lung: A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Bronchial Neoplasms: Tumors or cancer of the BRONCHI.Cell Division: The fission of a CELL. It includes CYTOKINESIS, when the CYTOPLASM of a cell is divided, and CELL NUCLEUS DIVISION.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Tissue Array Analysis: The simultaneous analysis of multiple samples of TISSUES or CELLS from BIOPSY or in vitro culture that have been arranged in an array format on slides or microchips.Disease-Free Survival: Period after successful treatment in which there is no appearance of the symptoms or effects of the disease.Keratins: A class of fibrous proteins or scleroproteins that represents the principal constituent of EPIDERMIS; HAIR; NAILS; horny tissues, and the organic matrix of tooth ENAMEL. Two major conformational groups have been characterized, alpha-keratin, whose peptide backbone forms a coiled-coil alpha helical structure consisting of TYPE I KERATIN and a TYPE II KERATIN, and beta-keratin, whose backbone forms a zigzag or pleated sheet structure. alpha-Keratins have been classified into at least 20 subtypes. In addition multiple isoforms of subtypes have been found which may be due to GENE DUPLICATION.Cisplatin: An inorganic and water-soluble platinum complex. After undergoing hydrolysis, it reacts with DNA to produce both intra and interstrand crosslinks. These crosslinks appear to impair replication and transcription of DNA. The cytotoxicity of cisplatin correlates with cellular arrest in the G2 phase of the cell cycle.Time Factors: Elements of limited time intervals, contributing to particular results or situations.RNA, Neoplasm: RNA present in neoplastic tissue.Follow-Up Studies: Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.Mutation: Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations.Cell Transformation, Neoplastic: Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.Transplantation, Heterologous: Transplantation between animals of different species.Biopsy: Removal and pathologic examination of specimens in the form of small pieces of tissue from the living body.Tomography, X-Ray Computed: Tomography using x-ray transmission and a computer algorithm to reconstruct the image.Antibodies, Monoclonal: Antibodies produced by a single clone of cells.Ki-67 Antigen: A CELL CYCLE and tumor growth marker which can be readily detected using IMMUNOCYTOCHEMISTRY methods. Ki-67 is a nuclear antigen present only in the nuclei of cycling cells.Genes, p53: Tumor suppressor genes located on the short arm of human chromosome 17 and coding for the phosphoprotein p53.Adenocarcinoma, Papillary: An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)Chemoembolization, Therapeutic: Administration of antineoplastic agents together with an embolizing vehicle. This allows slow release of the agent as well as obstruction of the blood supply to the neoplasm.Fatal Outcome: Death resulting from the presence of a disease in an individual, as shown by a single case report or a limited number of patients. This should be differentiated from DEATH, the physiological cessation of life and from MORTALITY, an epidemiological or statistical concept.Blotting, Western: Identification of proteins or peptides that have been electrophoretically separated by blot transferring from the electrophoresis gel to strips of nitrocellulose paper, followed by labeling with antibody probes.Base Sequence: The sequence of PURINES and PYRIMIDINES in nucleic acids and polynucleotides. It is also called nucleotide sequence.Loss of Heterozygosity: The loss of one allele at a specific locus, caused by a deletion mutation; or loss of a chromosome from a chromosome pair, resulting in abnormal HEMIZYGOSITY. It is detected when heterozygous markers for a locus appear monomorphic because one of the ALLELES was deleted.Mammary Neoplasms, Experimental: Experimentally induced mammary neoplasms in animals to provide a model for studying human BREAST NEOPLASMS.Kaplan-Meier Estimate: A nonparametric method of compiling LIFE TABLES or survival tables. It combines calculated probabilities of survival and estimates to allow for observations occurring beyond a measurement threshold, which are assumed to occur randomly. Time intervals are defined as ending each time an event occurs and are therefore unequal. (From Last, A Dictionary of Epidemiology, 1995)Neovascularization, Pathologic: A pathologic process consisting of the proliferation of blood vessels in abnormal tissues or in abnormal positions.Carcinoma, Basosquamous: A skin carcinoma that histologically exhibits both basal and squamous elements. (From Dorland, 27th ed)Receptor, erbB-2: A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.Thyroidectomy: Surgical removal of the thyroid gland. (Dorland, 28th ed)Carcinoembryonic Antigen: A glycoprotein that is secreted into the luminal surface of the epithelia in the gastrointestinal tract. It is found in the feces and pancreaticobiliary secretions and is used to monitor the response to colon cancer treatment.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Genes, Tumor Suppressor: Genes that inhibit expression of the tumorigenic phenotype. They are normally involved in holding cellular growth in check. When tumor suppressor genes are inactivated or lost, a barrier to normal proliferation is removed and unregulated growth is possible.Neoplasms, Experimental: Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.Breast: In humans, one of the paired regions in the anterior portion of the THORAX. The breasts consist of the MAMMARY GLANDS, the SKIN, the MUSCLES, the ADIPOSE TISSUE, and the CONNECTIVE TISSUES.Gene Expression Profiling: The determination of the pattern of genes expressed at the level of GENETIC TRANSCRIPTION, under specific circumstances or in a specific cell.Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)Cadherins: Calcium-dependent cell adhesion proteins. They are important in the formation of ADHERENS JUNCTIONS between cells. Cadherins are classified by their distinct immunological and tissue specificities, either by letters (E- for epithelial, N- for neural, and P- for placental cadherins) or by numbers (cadherin-12 or N-cadherin 2 for brain-cadherin). Cadherins promote cell adhesion via a homophilic mechanism as in the construction of tissues and of the whole animal body.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Papillomaviridae: A family of small, non-enveloped DNA viruses infecting birds and most mammals, especially humans. They are grouped into multiple genera, but the viruses are highly host-species specific and tissue-restricted. They are commonly divided into hundreds of papillomavirus "types", each with specific gene function and gene control regions, despite sequence homology. Human papillomaviruses are found in the genera ALPHAPAPILLOMAVIRUS; BETAPAPILLOMAVIRUS; GAMMAPAPILLOMAVIRUS; and MUPAPILLOMAVIRUS.Rectal Neoplasms: Tumors or cancer of the RECTUM.Adenocarcinoma, Bronchiolo-Alveolar: A carcinoma thought to be derived from epithelium of terminal bronchioles, in which the neoplastic tissue extends along the alveolar walls and grows in small masses within the alveoli. Involvement may be uniformly diffuse and massive, or nodular, or lobular. The neoplastic cells are cuboidal or columnar and form papillary structures. Mucin may be demonstrated in some of the cells and in the material in the alveoli, which also includes denuded cells. Metastases in regional lymph nodes, and in even more distant sites, are known to occur, but are infrequent. (From Stedman, 25th ed)Tumor Suppressor Proteins: Proteins that are normally involved in holding cellular growth in check. Deficiencies or abnormalities in these proteins may lead to unregulated cell growth and tumor development.Liver Neoplasms, Experimental: Experimentally induced tumors of the LIVER.Carcinoma, Pancreatic Ductal: Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.Adrenal Cortex Neoplasms: Tumors or cancers of the ADRENAL CORTEX.Urothelium: The epithelial lining of the URINARY TRACT.Vulvar Neoplasms: Tumors or cancer of the VULVA.Signal Transduction: The intracellular transfer of information (biological activation/inhibition) through a signal pathway. In each signal transduction system, an activation/inhibition signal from a biologically active molecule (hormone, neurotransmitter) is mediated via the coupling of a receptor/enzyme to a second messenger system or to an ion channel. Signal transduction plays an important role in activating cellular functions, cell differentiation, and cell proliferation. Examples of signal transduction systems are the GAMMA-AMINOBUTYRIC ACID-postsynaptic receptor-calcium ion channel system, the receptor-mediated T-cell activation pathway, and the receptor-mediated activation of phospholipases. Those coupled to membrane depolarization or intracellular release of calcium include the receptor-mediated activation of cytotoxic functions in granulocytes and the synaptic potentiation of protein kinase activation. Some signal transduction pathways may be part of larger signal transduction pathways; for example, protein kinase activation is part of the platelet activation signal pathway.Transfection: The uptake of naked or purified DNA by CELLS, usually meaning the process as it occurs in eukaryotic cells. It is analogous to bacterial transformation (TRANSFORMATION, BACTERIAL) and both are routinely employed in GENE TRANSFER TECHNIQUES.Oropharyngeal Neoplasms: Tumors or cancer of the OROPHARYNX.Receptor, Epidermal Growth Factor: A cell surface receptor involved in regulation of cell growth and differentiation. It is specific for EPIDERMAL GROWTH FACTOR and EGF-related peptides including TRANSFORMING GROWTH FACTOR ALPHA; AMPHIREGULIN; and HEPARIN-BINDING EGF-LIKE GROWTH FACTOR. The binding of ligand to the receptor causes activation of its intrinsic tyrosine kinase activity and rapid internalization of the receptor-ligand complex into the cell.Gene Expression: The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION.Case-Control Studies: Studies which start with the identification of persons with a disease of interest and a control (comparison, referent) group without the disease. The relationship of an attribute to the disease is examined by comparing diseased and non-diseased persons with regard to the frequency or levels of the attribute in each group.Tumor Burden: The total amount (cell number, weight, size or volume) of tumor cells or tissue in the body.Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.Down-Regulation: A negative regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.Receptors, Estrogen: Cytoplasmic proteins that bind estrogens and migrate to the nucleus where they regulate DNA transcription. Evaluation of the state of estrogen receptors in breast cancer patients has become clinically important.Phenylurea Compounds: Compounds that include the amino-N-phenylamide structure.Xenograft Model Antitumor Assays: In vivo methods of screening investigative anticancer drugs, biologic response modifiers or radiotherapies. Human tumor tissue or cells are transplanted into mice or rats followed by tumor treatment regimens. A variety of outcomes are monitored to assess antitumor effectiveness.Risk Factors: An aspect of personal behavior or lifestyle, environmental exposure, or inborn or inherited characteristic, which, on the basis of epidemiologic evidence, is known to be associated with a health-related condition considered important to prevent.Neoplasm Grading: Methods which attempt to express in replicable terms the level of CELL DIFFERENTIATION in neoplasms as increasing ANAPLASIA correlates with the aggressiveness of the neoplasm.Bile Duct Neoplasms: Tumors or cancer of the BILE DUCTS.Carcinoma, Giant Cell: An epithelial neoplasm characterized by unusually large anaplastic cells. It is highly malignant with fulminant clinical course, bizarre histologic appearance and poor prognosis. It is most common in the lung and thyroid. (From Stedman, 25th ed & Segen, Dictionary of Modern Medicine, 1992)Urologic Neoplasms: Tumors or cancer of the URINARY TRACT in either the male or the female.Niacinamide: An important compound functioning as a component of the coenzyme NAD. Its primary significance is in the prevention and/or cure of blacktongue and PELLAGRA. Most animals cannot manufacture this compound in amounts sufficient to prevent nutritional deficiency and it therefore must be supplemented through dietary intake.Gene Amplification: A selective increase in the number of copies of a gene coding for a specific protein without a proportional increase in other genes. It occurs naturally via the excision of a copy of the repeating sequence from the chromosome and its extrachromosomal replication in a plasmid, or via the production of an RNA transcript of the entire repeating sequence of ribosomal RNA followed by the reverse transcription of the molecule to produce an additional copy of the original DNA sequence. Laboratory techniques have been introduced for inducing disproportional replication by unequal crossing over, uptake of DNA from lysed cells, or generation of extrachromosomal sequences from rolling circle replication.Papilloma: A circumscribed benign epithelial tumor projecting from the surrounding surface; more precisely, a benign epithelial neoplasm consisting of villous or arborescent outgrowths of fibrovascular stroma covered by neoplastic cells. (Stedman, 25th ed)Keratin-7: A type II keratin found associated with KERATIN-19 in ductal epithelia and gastrointestinal epithelia.Cell Line: Established cell cultures that have the potential to propagate indefinitely.In Situ Hybridization, Fluorescence: A type of IN SITU HYBRIDIZATION in which target sequences are stained with fluorescent dye so their location and size can be determined using fluorescence microscopy. This staining is sufficiently distinct that the hybridization signal can be seen both in metaphase spreads and in interphase nuclei.Benzenesulfonates: Organic salts and esters of benzenesulfonic acid.Ureteral Neoplasms: Cancer or tumors of the URETER which may cause obstruction leading to hydroureter, HYDRONEPHROSIS, and PYELONEPHRITIS. HEMATURIA is a common symptom.Lymph Nodes: They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system.DNA Mutational Analysis: Biochemical identification of mutational changes in a nucleotide sequence.Hepatectomy: Excision of all or part of the liver. (Dorland, 28th ed)Mice, Inbred BALB CUp-Regulation: A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins.Cell Survival: The span of viability of a cell characterized by the capacity to perform certain functions such as metabolism, growth, reproduction, some form of responsiveness, and adaptability.Nephrectomy: Excision of kidney.Predictive Value of Tests: In screening and diagnostic tests, the probability that a person with a positive test is a true positive (i.e., has the disease), is referred to as the predictive value of a positive test; whereas, the predictive value of a negative test is the probability that the person with a negative test does not have the disease. Predictive value is related to the sensitivity and specificity of the test.Proto-Oncogene Proteins: Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity.Promoter Regions, Genetic: DNA sequences which are recognized (directly or indirectly) and bound by a DNA-dependent RNA polymerase during the initiation of transcription. Highly conserved sequences within the promoter include the Pribnow box in bacteria and the TATA BOX in eukaryotes.Adenoma, Oxyphilic: A usually benign glandular tumor composed of oxyphil cells, large cells with small irregular nuclei and dense acidophilic granules due to the presence of abundant MITOCHONDRIA. Oxyphil cells, also known as oncocytes, are found in oncocytomas of the kidney, salivary glands, and endocrine glands. In the thyroid gland, oxyphil cells are known as Hurthle cells and Askanazy cells.Carcinosarcoma: A malignant neoplasm that contains elements of carcinoma and sarcoma so extensively intermixed as to indicate neoplasia of epithelial and mesenchymal tissue. (Stedman, 25th ed)Neoplasms: New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.Microsatellite Repeats: A variety of simple repeat sequences that are distributed throughout the GENOME. They are characterized by a short repeat unit of 2-8 basepairs that is repeated up to 100 times. They are also known as short tandem repeats (STRs).Adenocarcinoma, Scirrhous: An adenocarcinoma with a hard (Greek skirrhos, hard) structure owing to the formation of dense connective tissue in the stroma. (From Dorland, 27th ed)Eyelid Neoplasms: Tumors of cancer of the EYELIDS.Chromosomes, Human, Pair 3: A specific pair of human chromosomes in group A (CHROMOSOMES, HUMAN, 1-3) of the human chromosome classification.Papillomavirus Infections: Neoplasms of the skin and mucous membranes caused by papillomaviruses. They are usually benign but some have a high risk for malignant progression.Multivariate Analysis: A set of techniques used when variation in several variables has to be studied simultaneously. In statistics, multivariate analysis is interpreted as any analytic method that allows simultaneous study of two or more dependent variables.Carcinoma, Ehrlich Tumor: A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.Mucin-1: Carbohydrate antigen elevated in patients with tumors of the breast, ovary, lung, and prostate as well as other disorders. The mucin is expressed normally by most glandular epithelia but shows particularly increased expression in the breast at lactation and in malignancy. It is thus an established serum marker for breast cancer.Cell Movement: The movement of cells from one location to another. Distinguish from CYTOKINESIS which is the process of dividing the CYTOPLASM of a cell.Transcription Factors: Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process.In Situ Hybridization: A technique that localizes specific nucleic acid sequences within intact chromosomes, eukaryotic cells, or bacterial cells through the use of specific nucleic acid-labeled probes.DNA-Binding Proteins: Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases.Teratoma: A true neoplasm composed of a number of different types of tissue, none of which is native to the area in which it occurs. It is composed of tissues that are derived from three germinal layers, the endoderm, mesoderm, and ectoderm. They are classified histologically as mature (benign) or immature (malignant). (From DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1642)Cystadenocarcinoma, Papillary: An adenocarcinoma in which the tumor elements are arranged as finger-like processes or as a solid spherical nodule projecting from an epithelial surface.Ampulla of Vater: A dilation of the duodenal papilla that is the opening of the juncture of the COMMON BILE DUCT and the MAIN PANCREATIC DUCT, also known as the hepatopancreatic ampulla.Nuclear Proteins: Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus.Oligonucleotide Array Sequence Analysis: Hybridization of a nucleic acid sample to a very large set of OLIGONUCLEOTIDE PROBES, which have been attached individually in columns and rows to a solid support, to determine a BASE SEQUENCE, or to detect variations in a gene sequence, GENE EXPRESSION, or for GENE MAPPING.Neoplasms, Squamous Cell: Neoplasms of the SQUAMOUS EPITHELIAL CELLS. The concept does not refer to neoplasms located in tissue composed of squamous elements.Carcinoma, Skin Appendage: A malignant tumor of the skin appendages, which include the hair, nails, sebaceous glands, sweat glands, and the mammary glands. (From Dorland, 27th ed)Common Bile Duct Neoplasms: Tumor or cancer of the COMMON BILE DUCT including the AMPULLA OF VATER and the SPHINCTER OF ODDI.Mammary Neoplasms, Animal: Tumors or cancer of the MAMMARY GLAND in animals (MAMMARY GLANDS, ANIMAL).RNA, Small Interfering: Small double-stranded, non-protein coding RNAs (21-31 nucleotides) involved in GENE SILENCING functions, especially RNA INTERFERENCE (RNAi). Endogenously, siRNAs are generated from dsRNAs (RNA, DOUBLE-STRANDED) by the same ribonuclease, Dicer, that generates miRNAs (MICRORNAS). The perfect match of the siRNAs' antisense strand to their target RNAs mediates RNAi by siRNA-guided RNA cleavage. siRNAs fall into different classes including trans-acting siRNA (tasiRNA), repeat-associated RNA (rasiRNA), small-scan RNA (scnRNA), and Piwi protein-interacting RNA (piRNA) and have different specific gene silencing functions.Polymorphism, Single-Stranded Conformational: Variation in a population's DNA sequence that is detected by determining alterations in the conformation of denatured DNA fragments. Denatured DNA fragments are allowed to renature under conditions that prevent the formation of double-stranded DNA and allow secondary structure to form in single stranded fragments. These fragments are then run through polyacrylamide gels to detect variations in the secondary structure that is manifested as an alteration in migration through the gels.Pharyngeal Neoplasms: Tumors or cancer of the PHARYNX.Iodine Radioisotopes: Unstable isotopes of iodine that decay or disintegrate emitting radiation. I atoms with atomic weights 117-139, except I 127, are radioactive iodine isotopes.Hypopharyngeal Neoplasms: Tumors or cancer of the HYPOPHARYNX.Cell Differentiation: Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs.

Overexpression of fibroblast growth factor receptor 3 in a human thyroid carcinoma cell line results in overgrowth of the confluent cultures. (1/1566)

Recent reports indicate that a gain-of-function mutation in fibroblast growth factor receptor 3 (FGFR-3) inhibits cell growth in the cartilaginous growth plates. These results suggest that FGFR-3 may be the receptor transducing growth inhibitory signals. Using reverse transcription-PCR we examined seven papillary thyroid carcinomas to determine FGFR-3 expression. Six out of the seven papillary carcinomas expressed FGFR-3. To clarify the role of FGFR-3 in thyroid carcinoma, FGFR-3 was overexpressed in an established human papillary thyroid carcinoma cell line. High levels of FGFR-3 protein were identified in cells stably transfected with the vector containing FGFR-3 cDNA. The specific binding of 125I-FGF-2 of these cells was threefold higher than that of control cells. Growth rates of cells overexpressing FGFR-3 were similar to those of control cells. However, cells overexpressing FGFR-3 continued to grow beyond the density at which control cells stopped proliferating. These results suggest that FGFR-3 in thyroid carcinoma is not involved strongly in the cell proliferation mechanism but may contribute to the malignant extension of some of the carcinomas by modifying cell contact signaling.  (+info)

Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. (2/1566)

In order to understand the origin of bladder cancer, very early urothelial lesions must be investigated in addition to more advanced tumors. Tissue from 31 biopsies of 12 patients with urothelial hyperplasias and simultaneous or consecutive superficial papillary tumors were used to microdissect urothelium from 15- microm sections of biopsies. The biopsies were obtained with the recently developed highly sensitive diagnostic method of 5-aminolevulinic acid-induced fluorescence endoscopy (AFE). Besides flat and papillary urothelial neoplasms, the method of photodynamic diagnostics also detects simple urothelial hyperplasias as fluorescent positive lesions. In addition, 12 fluorescence-positive biopsies showing histologically normal urothelium were investigated. Fluorescence in situ hybridization was done using a dual color staining technique of biotinylated centromeric probes of chromosomes 9 and 17 and digoxigenin-labeled gene-specific P1 probes for chromosomes 9q22 (FACC), 9p21(p16/CDKI2), and 17p13(p53). Ten of 14 hyperplasias (70%) showed deletions of chromosome 9. In 7 out of 8 patients with genetic alterations in the hyperplasias the genetic change was also present in the papillary tumor. Six out of 12 samples of microdissected normal urothelium also showed genetic alterations on chromosome 9. Microdissection of urothelial lesions, obtained during AFE, has led to the first unequivocal documentation of genetic changes in urothelial lesions diagnosed as normal in histopathology. Thus, this technical approach is important to provide insight into the earliest molecular alterations in bladder carcinogenesis.  (+info)

A new rapid technique for the fixation of thyroid gland surgical specimens. (3/1566)

One of the main diagnostic problems in thyroid pathology is to distinguish between follicular adenoma and follicular carcinoma. Thorough sampling of the nodule's capsule is recommended in order to identify capsular invasion. However, during the hardening of the tissue, by the usual fixatives the capsule shrinks and rolls downwards and sometimes the capsule separates from the remaining tissue. The present work evaluates the use of "Lymph Node Revealing Solution" (LNRS) for the rapid fixation (2h) of different thyroid lesions as compared to that of formalin. Fifty-one unselected consecutive cases of thyroid nodules, which included various benign and malignant lesions, were examined. Each specimen was cut in two equal parts; one was fixed in LNRS, the other in formalin. Fixation in LNRS for 2 hours gave adequate results in sectioning and staining of the tissue, and excellent immunostains. Its advantage over formalin is the conservation of the natural relationship between the capsule and the rest of the tissue, on the same plane, as well as the short time required for the final diagnosis.  (+info)

Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53. (4/1566)

Differentiated thyroid carcinomas (in contrast to the rarer anaplastic form) are unusual among human cancers in displaying a remarkably low frequency of p53 mutation and appear to retain wild-type (wt) p53 function as assessed by the response of derived cell lines to DNA damage. Using one such cell line, K1, we have tested the effect of experimental abrogation of p53 function by generating matched sub-clones stably expressing either a neo control gene, a dominant-negative mutant p53 (143ala) or human papilloma virus protein HPV16 E6. Loss of p53 function in the latter two groups was confirmed by abolition of p53-dependent 'stress' responses including induction of the cyclin/CDK inhibitor p21WAF1 and G1/S arrest following DNA-damage. In contrast, no change was detected in the phenotype of 'unstressed' clones, with respect to any of the following parameters: proliferation rate in monolayer, serum-dependence for proliferation or survival, tumorigenicity, cellular morphology, or tissue-specific differentiation markers. The K1 line therefore represents a 'neutral' background with respect to p53 function, permitting the derivation of functionally p53 + or - clones which are not only iso-genic but also iso-phenotypic. Such a panel should be an ideal tool with which to test the p53-dependence of cellular stress responses, particularly the sensitivity to potential therapeutic agents, free from the confounding additional phenotypic differences which usually accompany loss of p53 function. The results also further support the hypothesis that p53 mutation alone is not sufficient to drive progression of thyroid cancer to the aggressive anaplastic form.  (+info)

Tissue inhibitor of metalloproteinases-1 (TIMP-1) mRNA is elevated in advanced stages of thyroid carcinoma. (5/1566)

Tumour cell invasion and metastasis is a multistep process that involves the degradation of extracellular matrix proteins by matrix metalloproteinases (MMPs). Tissue inhibitors of metalloproteinases (TIMPs) act as negative regulators of MMPs and thus prevent tumour cell invasion and metastasis by preserving extracellular matrix (ECM) integrity. In the present study we examined the expression of one member of TIMPs, TIMP-1, in 39 thyroid tumour specimens and two thyroid carcinoma cell lines (NPA and SW579). We also investigated the effect of high TIMP-1 expression on the invasive potential of NPA cells. Northern blot analysis showed that TIMP-1 mRNA levels correlated directly with tumour aggressiveness: the highest number of TIMP-1 transcripts was found in stages III and IV vs benign goitre (P < 0.0001). However, TIMP-1 expression was not increased in NPA and SW579 cells, both of which are derived from poorly differentiated thyroid tumours. Immunohistochemical study showed strong TIMP-1 staining in the stroma cells of advanced stages of carcinomas. Overexpression of TIMP-1 by gene transfer resulted in a significant suppression of the malignant phenotype of NPA cells as judged by an in vitro tumour invasion assay. These results suggest that high levels of TIMP-1 transcripts in advanced stages of thyroid carcinoma likely come from stroma rather than thyroid cancer cells, and TIMP-1 may function as a thyroid tumour invasion/metastasis suppressor.  (+info)

Elevated reticulocyte count--a clue to the diagnosis of haemolytic-uraemic syndrome (HUS) associated with gemcitabine therapy for metastatic duodenal papillary carcinoma: a case report. (6/1566)

In adults, the haemolytic-uraemic syndrome (HUS) is associated with probable causative factors in the minority of all cases. Cytotoxic drugs are one of these potential causative agents. Although metastatic cancer by itself is a recognized risk-factor for the development of HUS, therapy with mitomycin-C, with cis-platinum, and with bleomycin carries a significant, albeit extremely small, risk for the development of HUS, compared with all other cytotoxic drugs. Gemcitabine is a novel cytotoxic drug with promising activity against pancreatic adenocarcinoma. We are reporting on one patient with metastatic duodenal papillary carcinoma developing HUS while on weekly gemcitabine therapy. The presenting features in this patient were non-cardiac pulmonary oedema, renal failure, thrombocytopenia and haemolytic anaemia. The diagnosis of HUS was made on the day of admission of the patient to this institution. Upon aggressive therapy, including one single haemodialysis and five plasmaphereses, the patient recovered uneventfully, with modestly elevated creatinine-values as a remnant of the acute illness. Re-exposure to gemcitabine 6 months after the episode of HUS instituted for progressive carcinoma, thus far has not caused another episode of HUS.  (+info)

Induction of mammary carcinomas by N-methyl-N-nitrosourea in ovariectomized rats treated with epidermal growth factor. (7/1566)

The importance of epidermal growth factor (EGF) in both normal and malignant mammary gland development are presented in these studies. Initial findings demonstrated that in the absence of ovarian hormones, EGF had a significant proliferative effect on mammary epithelial cells. To determine whether mammary epithelial cells grown with EGF, in the absence of ovarian hormones, could be transformed by N-methyl-N-nitrosourea (MNU), female ovariectomized Lewis rats were implanted with pellets containing EGF for 1 week and then treated with MNU for initiation. Two days after MNU treatment, ovaries were implanted and EGF pellets were removed from all ovariectomized groups in order to promote carcinogenesis. The mammary carcinoma incidence of the EGF-stimulated group (90%) was not significantly different from the intact group (100%). The mammary cancer morphology of EGF-treated carcinomas was either ductal carcinoma or cribriform adenocarcinoma, whereas intact animals developed mainly papillary and occasional cribriform carcinomas. Fifty-eight percent of the carcinomas from the EGF group were ovarian hormone-independent compared with 10% of carcinomas from the intact group. These results demonstrate that EGF-induced proliferation during initiation with MNU was sufficient to induce the transformation of mammary carcinomas in the absence of ovarian hormones. The hormonal dependency of these EGF-induced carcinomas were different compared with MNU-initiated mammary carcinomas in intact rats.  (+info)

The genetic locus NRC-1 within chromosome 3p12 mediates tumor suppression in renal cell carcinoma independently of histological type, tumor microenvironment, and VHL mutation. (8/1566)

Human chromosome 3p cytogenetic abnormalities and loss of heterozygosity have been observed at high frequency in the nonpapillary form of sporadic renal cell carcinoma (RCC). The von Hippel-Lindau (VHL) gene has been identified as a tumor suppressor gene for RCC at 3p25, and functional studies as well as molecular genetic and cytogenetic analyses have suggested as many as two or three additional regions of 3p that could harbor tumor suppressor genes for sporadic RCC. We have previously functionally defined a novel genetic locus nonpapillary renal carcinoma-1 (NRC-1) within chromosome 3p12, distinct from the VHL gene, that mediates tumor suppression and rapid cell death of RCC cells in vivo. We now report the suppression of tumorigenicity of RCC cells in vivo after the transfer of a defined centric 3p fragment into different histological types of RCC. Results document the functional involvement of NRC-1 in not only different cell types of RCC (i.e., clear cell, mixed granular cell/clear cell, and sarcomatoid types) but also in papillary RCC, a less frequent histological type of RCC for which chromosome 3p LOH and genetic aberrations have only rarely been observed. We also report that the tumor suppression observed in functional genetic screens was independent of the microenvironment of the tumor, further supporting a role for NRC-1 as a more general mediator of in vivo growth control. Furthermore, this report demonstrates the first functional evidence for a VHL-independent pathway to tumorigenesis in the kidney via the genetic locus NRC-1.  (+info)

TY - JOUR. T1 - Peripheral location and infiltrative margin predict invasive features of papillary thyroid microcarcinoma. AU - Lee, Woo Kyung. AU - Lee, Jandee. AU - Kim, Hyunji. AU - Lee, Seul Gi. AU - Choi, Sun Hyung. AU - Jeong, Seonhyang. AU - Kwon, Hyeong Ju. AU - Jung, Sang Geun. AU - Jo, Young Suk. PY - 2019. Y1 - 2019. N2 - Objective: Tumor location in papillary thyroid microcarcinoma (PTMC) might determine tumor outgrowth from the thyroid gland. However, the clinical implications of tumor location and minimal extrathyroid extension (mETE) have not been well elucidated. We aimed to investigate the relationship between tumor location and mETE to predict the aggressiveness of PTMC. Methods: A total of 858 patients with PTMC were grouped according to tumor location on ultrasonography: central (cPTMC) and peripheral PTMC (pPTMC). PTMC without mETE (PTMC-mETE(-)) was divided further according to margin shape: encapsulated (E-) or infiltrative (I-). To understand the molecular biologic ...
TY - JOUR. T1 - Clinicopathologic features and outcomes in patients with diffuse sclerosing variant of papillary thyroid carcinoma. AU - Akaishi, Junko. AU - Sugino, Kiminori. AU - Kameyama, Kaori. AU - Masaki, Chie. AU - Matsuzu, Kenichi. AU - Suzuki, Akifumi. AU - Uruno, Takashi. AU - Ohkuwa, Keiko. AU - Shibuya, Hiroshi. AU - Kitagawa, Wataru. AU - Nagahama, Mitsuji. AU - Shimizu, Kazuo. AU - Ito, Koichi. PY - 2015/7/5. Y1 - 2015/7/5. N2 - Background: Diffuse sclerosing variant (DSV) of papillary thyroid carcinoma (PTC) is a rare variant more common among younger patients. Materials and methods: Excluding patients with microcarcinoma, 5848 patients with PTC underwent initial surgery between 1995 and 2011. Twenty-two patients (0.4 %) were histologically diagnosed with DSV, of whom 20 (91 %) were ,45 years old. We compared clinicopathologic characteristics and outcomes between patients with DSV and those with classical PTC ,45 years old. Univariate analysis by the Kaplan-Meier method in ...
TY - JOUR. T1 - Cytologic features of infarcted thyroid papillary carcinoma induced by fine needle aspiration. AU - Jang, Se Min. AU - Jun, Young Jin. AU - Na, Woong. AU - Jang, Ki Seok. AU - Paik, Seung Sam. PY - 2010/1/1. Y1 - 2010/1/1. KW - Aspiration biopsy, fine-needle. KW - Carcinoma, papillary. KW - Infarction. KW - Thyroid neoplasms. UR - http://www.scopus.com/inward/record.url?scp=78650508591&partnerID=8YFLogxK. M3 - Letter. C2 - 21053614. AN - SCOPUS:78650508591. VL - 54. SP - 1082. EP - 1083. JO - Acta Cytologica. JF - Acta Cytologica. SN - 0001-5547. IS - 5. ER - ...
Nuclear retinoid receptors (RARs) upon a ligand binding act as all-trans retinoic acid-inducible transcription factors interacting as conditional heterodimers with nuclear retinoid X (rexinoid) receptors (RXRs). The disruption of retinoic acid (RA) signalling pathways is believed to underlie the etiology of a number of malignancies. RAR and RXR ligands are known to play role in reprogramming several tumour cells, and thus the development of appropriate ligands with reduced teratogenic and other side effects are still highly required. In this study, we have investigated expression pattern of retinoid receptor subtypes (RARalpha, RARbeta, RARgamma) and retinoid X nuclear receptor subtypes (RXRalpha, RXRbeta, RXRgamma) in three different human organ malignancies, i) thyroid papillary carcinoma, ii) breast cancer, and iii) renal carcinoma.. ...
Papillary squamous cell carcinoma (PSCC) of the uterine cervix is difficult to diagnose due to its rarity and limited data regarding its clinical behavior. We attempted to assess the degree of stromal invasion using magnetic resonance imaging (MRI) and evaluate possible treatments for this lesion in view of its clinical behavior. We analyzed 28 cases of PSCC diagnosed on the colposcopic selective biopsies. We studied the rate of accuracy of diagnoses of the colposcopic selective biopsies compared with the final diagnoses, and compared the rate of stromal invasion between the MRI and pathological findings while focusing on surgical methods and the clinical prognosis. Of the 28 patients, only 12 exhibited true PSCC. The other 16 patients were ultimately diagnosed with SCC or adenosquamous carcinoma based on the finding of the surgical specimens and exhibited relatively poor prognoses. Among the 12 true PSCC cases, the rate of diagnostic accuracy of stromal invasion (with or without) was only 58% (7/12) on
Papillary carcinoma of the breast is an extremely rare variety of carcinoma breast with a mere incidence of only 0.5% of all recently diagnosed cases of breast cancer. We present a case of 63 years old postmenopausal female who came to the surgical outpatient department with complaints of a slowly increasing mass in the left breast of 1-month duration which was painless. A Left-sided modified radical mastectomy was performed with an absolutely normal post-operative period. The final histopathology report was suggestive of invasive papillary carcinoma. We report this case as it is rarely diagnosed. KEYWORDS: Invasive papillary carcinoma, modified radical mastectomy, carcinoma breast.. ...
TY - JOUR. T1 - Is invasive micropapillary serous carcinoma a low-grade carcinoma?. AU - Ohishi, Yoshihiro. AU - Imamura, Hiroko. AU - Aman, Murasaki. AU - Shida, Kaai. AU - Kaku, Tsunehisa. AU - Kato, Kiyoko. AU - Oda, Yoshinao. PY - 2016/1/1. Y1 - 2016/1/1. N2 - "Invasive micropapillary serous carcinoma" has been proposed as a synonym for low-grade serous carcinoma by some expert pathologists. In contrast, Singer and colleagues reported that some serous carcinomas with conspicuous invasive micropapillary pattern (SC-IMPs) can show high-grade nuclear atypia. However, the molecular features of such tumors have not been well documented. The aim of this study was to demonstrate and emphasize the fact that high-grade serous carcinoma confirmed by immunohistochemistry and molecular analysis can show conspicuous invasive micropapillary pattern. We selected 24 "SC-IMPs" and investigated: (1) their morphologic features; (2) the immunostaining pattern of p53 protein; and (3) KRAS/BRAF/TP53 gene ...
history of IgG monoclonal gamopathy. An ultrasound of the thyroid showed a 10 mm diameter nodule to the right and a 12 mm diameter nodule ... and the prognosis is excellent (in the case the tumor is papillary carcinoma- the most common thyroid malignancy). To conclude- .... ...
Extrathyroidal extension was more frequent in DSV than in TCV and cPTC patients (p < 0.05); moreover, only DSV tumors had a higher rate of recurrent/persistent disease when compared to cPTC treated with the same protocol (total thyroidectomy followed by (131)I treatment) (p < 0.01). After initial treatment, 54.2% of TCV and 20.4% of DSV patients were classified at low risk, while at ongoing risk stratification, the excellent response (low risk) was higher for both TCV (77.8%) and DSV (50.0%) patients relative to initial stratification (both p < 0.01). Using ongoing risk classification, positive predictive value (PPV) for persistent/recurrent disease was higher relative to initial risk stratification for both TCV (PPV = 93.8 vs. 39.4%) and DSV (PPV = 63.0 vs. 34.9%), p < 0.05 for both. CONCLUSIONS ...
But de l étude : le microcarcinome thyroïdien révélé par des adénopathies cervicales est fréquent et il s agit dans la majorité des cas du type papillaire
Intracystic papillary carcinoma of the breast associated with areas of infiltration, is a rare, constituting less than 1% of breast cancers. These are tumors whose initial radiological study shows lesions with low suspicion of malignancy in a high proportion of cases. We present two cases of intracystic papillary carcinoma, associated with infiltration diagnosed at the Breast Unit of Hospital Infanta Cristina In both cases the reason for consultation was the palpation of a nodule and initial radiographic approach showed lesions with low suspicion of malignancy ...
The thyroid is the organ that has the greatest risk of malignant tumors among the endocrine tumors. The papillary carcinoma occupies 80% of the entire thyroid tumors. Immunohistochemical staining of galectin-3 has usually been used in differentiating papillary carcinoma and follicular carcinoma. The p53 gene of the cell cycle is a tumor suppressor gene acting in on the control points. The cyclin D1 genes in the cell cycle, involved in the implementation of G1 and S phase, plays an important role in the progression of thyroid tumors. This research compares and analyzes correlation between papillary carcinoma, follicular carcinoma, p53, cyclin D1 and galectin-3 gene expression patterns. In a total of 30 cases from papillary carcinoma, 21 cases from p53 (70%), 27 cases in galectin-3 (90%), and 26 cases in cyclin D1 (86.7%) showed positive rate. The galectin-3 staining investigated, showed a significant difference between a papillary carcinoma and a follicular carcinoma. Follicular carcinoma from 15 ...
TY - JOUR. T1 - Papillary carcinoma of the thyroid gland. AU - Baker, R. Robinson. AU - Hyland, J.. PY - 1985. Y1 - 1985. N2 - The results of this analysis have demonstrated that papillary carcinoma of the thyroid gland rarely causes the death of the patient. Bilateral subtotal lobectomies, partial lobectomies and probably total lobectomy combined with contralateral partial lobectomy should not be performed in the treatment of this disease. The incidence of local recurrence is higher after these procedures, and any subsequent operative procedure is complicated by scarring secondary to the initial procedure. Total lobectomy is the procedure of choice for patients with disease confined to one lobe on palpation. Total thyroidectomy should only be performed for palpable disease in both lobes. Excision of a grossly normal contralateral lobe solely to obtain microscopic tumor which rarely becomes clinically apparent is not worth the inherent risk of bilateral recurrent palsy of the nerve or permanent ...
JIM HSU, JAE Y. RO. The 2016 WHO classification of tumors of the urothelial tract recently revised the classification of invasive urothelial carcinoma to include nested, microcystic, micropapillary, plasmacytoid, sarcomatoid, giant cell, and poorly differentiated variants, among others. In particular, invasive micropapillary carcinoma (IMPC) is now recognized as a distinct entity with aggressive f
In 2016, Saleh [59] from Egypt, performed heterotopic autotransplantation of fresh thyroid tissue for 20 patients who underwent TT (13 with simple MNG, 4 with Graves disease and 3 with toxic nodular goiter). Intraoperatively, 10-15 g of the healthiest looking non-nodular part of the excised gland was minced into 1-2 mm slices after stripping of its fibrous capsule. The tissue was then made into an emulsion of 20 mL lactated Ringers solution and injected through the rectus femoris muscle in 6-8 different directions using a specially designed wide bore needle. The final postoperative pathology reported a follicular variant of thyroid papillary carcinoma in 2 patients in whom preoperative pathology missed their diagnosis. The 2 patients had their graft excised and were excluded from the study. Follow-up of 18 patients was done to report the survival and function of the heterotopic transplanted thyroid tissue through 99mTc uptake at 2-month postoperatively and thyroid function tests (FT3, FT4, and ...
Ms. Aida Antonio was 29 years old when I did a thyroidectomy on her thyroid papillary carcinoma. She is now 53 years old with no clinical evidence of recurrence. We both thank God for this long 24 years of remission.
The incidence of thyroid cancer is increasing globally. This is mainly due to the increase in the detection of small papillary carcinomas, including papillary microcarcinomas (PMC) 1 cm or smaller. It
Has anybody here been diagnosed with Papillary Carcinoma Thyroid Cancer that has affected the surrounding lymph nodes? My 21 y/o cousin was diagnosed and her thyroid along with lymph nodes were removed less than a month ago. The pathology report showed several nodules on the thyroid (2 on the left node 2x1x1 cm in size, and several on the right node with the biggest one being 2.5x2x1 cm). The lymph nodes removed some are tumor compromised, and some have extranodal extension. Shes having a 2nd
Every thyroid case is different, survival depends on many different factors like age, or how long you had cancer before discovery, etc. Im not a doctor. But I am a "Thyroid Cancer Survivor" x 21 years now. My cancer was "Papillary Carcinoma." From all that I have been told and read-- is that you can get thyroid cancer from being exposed to x-rays, especially if you had them when you were a child, it doesnt have to be because of Chernobyl. If you have had your surgery, you are on your road to recovery...for me, only one lobe had cancer, it was removed,the other lobe remained. No chemo was needed. The docs told me that I needed to have suppression therapy, they use Synthroid. They say-- that is because I still have one lobe left and there is a potential for cancer cells, suppressing the lobe will hopefully keep the cancer cells at bay for awhile. The other thing the docs are doing is keeping my TSH level low, ,1. Please keep your chin up, I wish you all the best with your health in the ...
Papillary carcinoma of the breast encompasses a spectrum of histologic subtypes. There are two common types: cystic (noninvasive form) and micropapillary ductal carcinoma (invasive form). Papillary br... more
I dont have an oncologist either, my endocrinologist specializes in treating thyroid cancer patients so I didnt see a need. You can talk to your endo about this, bring all the lab reports from your mamograms, sonograms and biopsy so he has something to look at. Your surgeon may also be very knowledgable about the questions you have, depending on his speciality.. I think if the breast cancer is metastic thyroid cancer they would have told you so, but best to ask to be certain.. Yes, I know what you mean, "lucky" to catch it early. I didnt know anything was wrong until I felt a swollen lymph node in my neck. Per doctors orders, I waited for a few months for it to go down, then spent another month waiting for the biopsy and found I had papillary. I had a TT and neck disection 2/11 and RAI 4/11. So far no recurrance, but well see. Theyre right when they say "lucky", if I had ignored the lump, Id probably be dealing with a larger metastic spread than just a couple of nodes in my neck. The thing ...
Thyroid carcinoma seems to have generated a considerable number of misconceptions. About 20% of these tumors are "pure" papillary, about 10% pure follicular, about 50% mixed papillary and follicular, and about 5% (range, 2%-10%) are called medullary. However, the pure papillary carcinoma usually has a few follicular elements if enough histologic sections are made, and […]. ...
OYAMA Tetsunari , SUZUKI Takeshi , HARA Futoshi , IINO Yuich , ISHIDA Tsunehiro , SAKAMOTO Atsuhiko , NAKAJIMA Takashi Pathology international 45(1), 45-50, 1995-01 医中誌Web 参考文献21件 被引用文献6件 ...
Treatment Options by Stage. Stage 0 (Papillary Carcinoma and Carcinoma in Situ). Treatment of stage 0 may include the following:. ...
By definition, clinical papillary carcinomas are 1. 60 The example indicates that cross-resistance is increased for hydrophilic drugs of moderate size.
Mutation of the BRAF gene is common in thyroid cancer. Follicular variant of papillary thyroid carcinoma is a variant of papillary thyroid carcinoma that has created continuous diagnostic controversies among pathologists. The aims of this study are to (1) investigate whether follicular variant of papillary thyroid carcinoma has a different pattern of BRAF mutation than conventional papillary thyroid carcinoma in a large cohort of patients with typical features of follicular variant of papillary thyroid carcinoma and (2) to study the relationship of clinicopathological features of papillary thyroid carcinomas with BRAF mutation. Tissue blocks from 76 patients with diagnostic features of papillary thyroid carcinomas (40 with conventional type and 36 with follicular variant) were included in the study. From these, DNA was extracted and BRAF V600E mutations were detected by polymerase chain reaction followed by restriction enzyme digestion and sequencing of exon 15. Analysis of the data indicated ...
Solid pseudopapillary tumors are rare, with the majority of described cases originating in the pancreas. To date, there are only 10 documented reports of primary ovarian solid pseudopapillary tumors. Here, we describe the case of a 24-year-old woman who presented with worsening pelvic pain and dysmenorrhea. Workup demonstrated a right ovarian solid mass on ultrasound and an elevated serum LDH, which raised concerns for dysgerminoma due to her relatively young age. Therefore, she was taken to the operating room and underwent laparoscopic right salpingo-oophorectomy. On initial rapid frozen section, her ovarian cyst had a grossly hemorrhagic appearance with multiple hemosiderin deposits noted microscopically, which suggested a benign hemorrhagic cyst. However, the final pathology was reported as solid pseudopapillary tumor based on several defining histologic characteristics. Most importantly, immunostaining was positive for |i|β|/i|-catenin and negative for E-cadherin. This report presents a brief
Although the vast majority of patients with Papillary Thyroid Microcarcinoma (PTMC) have excellent long-term outcomes, some patients experience tumor re
A collision tumor involving a tracheal sarcomatoid carcinoma and a papillary thyroid carcinoma has never been reported in the literature. A 78-year-old female presented with a large neck mass and hoarseness. A fine needle aspiration demonstrated papillary thyroid carcinoma. Imaging revealed a right thyroid mass invading into the tracheal lumen with bulky ipsilateral lymphadenopathy. The patient underwent a total thyroidectomy, tracheal resection, and central and right neck dissections. Pathology demonstrated a tracheal sarcomatoid carcinoma invading the right thyroid, which had multifocal papillary thyroid carcinoma with central and lateral neck metastases. The patient subsequently received adjuvant chemoradiotherapy and radioactive iodine. We present a case of a tracheal sarcomatoid carcinoma colliding with a papillary thyroid cancer. Treatment modalities should address the most aggressive tumor, while being tailored to clinical picture, tumor histology, and patient preferences.
A comprehensive analysis of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer: Confirmation of linkage to TCO1. About 5% of nonmedullary thyroid cancer is familial. These familial nonmedullary thyroid cancer cases are characterized by an earlier age of onset, more aggressive phenotype, and in some families a high propensity to benign thyroid disease. Little is known about the genes conferring predisposition to nonmedullary thyroid cancer. Three loci have been identified through genetic linkage: MNG1 on 14q32, TCO1 on 19p13.2, and fPTC on 1p21. In addition to these putative genes, a number of loci represent candidate familial nonmedullary thyroid cancer predisposition genes by virtue of their involvement in sporadic disease (TRKA), their role in benign disease (TSHR), and because they underlie syndromes with a risk of nonmedullary thyroid cancer (PTEN). To evaluate the roles of MNG1, TCO1, fPTC, PTEN, TSHR, and TRKA in familial nonmedullary thyroid cancer, we have ...
TY - JOUR. T1 - Tumor immune microenvironment characteristics of papillary thyroid carcinoma are associated with histopathological aggressiveness and BRAF mutation status. AU - Means, Casey. AU - Clayburgh, Daniel. AU - Maloney, Lauren. AU - Sauer, David. AU - Taylor, Matthew H.. AU - Shindo, Maisie. AU - Coussens, Lisa. AU - Tsujikawa, Takahiro. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Background: Papillary thyroid carcinoma (PTC) follows an indolent course; however, up to 30% of patients develop recurrent disease requiring further treatment. Profiling PTC immune complexity may provide new biomarkers for improved risk prediction. Methods: Immune complexity profiles were quantitatively evaluated by multiplex immunohistochemistry (mIHC) in archived tissue sections from 39 patients with PTC, and were assessed for correlations with aggressive histopathological features based on the presence of lymphovascular invasion and/or extrathyroidal extension, and BRAF V600E mutational status. Results: mIHC ...
Synchronous primary cancers are occasionally observed, but TTM is extremely rare; only about 100 cases have been reported in the English literature. Campbell et al. [7] proposed the concept of TTM, which can be distinguished from collision tumor based on following criteria: 1) more than one primary tumor; 2) the recipient tumor may be a true benign or malignant neoplasm; 3) the metastatic neoplasm is a true metastasis with established growth within the host tumor, not the result of contiguous growth (collision tumor) or tumor emboli; 4) primary tumors spreading into the lymphatic system in the setting of generalized lymphoreticular malignancy are excluded.. According to the seed and soil hypothesis [8] of cancer metastasis, interactions between cancer cells (seed) and specific organ microenvironments (soil) determine the outcome of metastasis. Renal cell carcinoma and meningioma are both highly vascularized tumors, and have high lipid and glycogen content, which can provide a fertile ...
Thyroid cancer, the commonest of endocrine malignancies, continues increasing in incidence being the 5th more prevalent cancer among women in the United States in 2012. Familial thyroid cancer has become a well-recognized, unique, clinical entity in patients with thyroid cancer originating from follicular cells, that is, nonmedullary thyroid carcinoma. Hereditary nonmedullary thyroid cancer may occur as a minor component of familial cancer syndromes (familial adenomatous polyposis, Gardners...
Objective: Describe a case of a patient diagnosed with papillary thyroid carcinoma by a retropharyngeal tumor.. Methods: A 46-year-old male was referred from the otorhinolaryngology consult to our department with the post-operative diagnosis of papillary thyroid carcinoma, with 6 months history of upper airway dyspnea and dysphagia to solids. Physical examination: right side adenopathies, not painful on palpation. No goitre. Laryngoscopy: hypertrophy of right posterior pharyngeal wall, epiglottis with rotation. Glotis was permeable. Mobile vocal cords. Pyriform sinus free. Cervical and thoracic TC: right retropharyngeal and internal jugular adenopathic conglomerates. Subcentimetrical mediastinal lymph nodes. Nasopharyngeal MRI: right retropharyngeal paracentral mass rejecting adjacent structures. FNA of cervical lymph node: lymph node with metastases of papillary thyroid carcinoma.. Results: Surgical treatment is decided. Transcervical excision was performed in right parapharyngeal tumor, ...
Introduction: We report an unusual case of adenocarcinoma of lung metachronous with stage IVA papillary thyroid carcinoma. The two tumors are morphologically similar; and the later presence of lung mass could clinically masquerade as metastatic thyroid carcinoma. We discuss the challenges in clinical, imaging and pathologic diagnosis. Case Report: A 64-year-old non-smoking female had a thyroidectomy and neck lymph node dissection for a stage IVA tumor with pathologic findings of one 2 mm microcarcinoma of left thyroid and six positive cervical lymph nodes. The post-surgical I131 whole body scan was negative and thyroglobulin is suppressed and stable (<1 ng/ml). One year later, she developed a ground glass and part-solid mass in the superior segment of left lower lobe of lung. The mass slowly grew increasing in size from 2.4 cm to 3.3 cm over 3 years. Biopsy of the lung lesion reveals morphologic features of nuclear inclusions and papillae similar to the previously diagnosed thyroid carcinoma. However,
|i|Background.|/i| Papillary thyroid carcinoma (PTC) is a form of thyroid cancer with high risk of cervical lymph node metastasis. |i|Aim.|/i| The aim of this study was to investigate the incidence and the predictive factors for occult ipsilateral central lymph node (CLN) metastasis in the patients with papillary thyroid carcinoma. |i|Methods.|/i| A total of 916 PTC patients (1017 lesions) undergoing central lymph node dissection in our hospital from 2005 to 2011 were enrolled. The relationship between CLN metastasis and clinical factors such as gender, age, tumor size, tumor number, capsule invasion, and tumor location was analyzed. |i|Results.|/i| Occult CLN metastasis was observed in 52.41% (533/1017) of PTC lesions, respectively. Multivariate analysis showed that age ≤ 35 years, tumor size > 1.5 cm, present capsule invasion/extracapsular invasion, and tumor located in upper/middle pole/whole lobe were risk factors of CLN metastasis. |i|Conclusions.|/i| Tumor located in upper
Through a transcriptome microarray analysis, we have isolated Anterior gradient protein 2 (AGR2) as a gene up-regulated in papillary thyroid carcinoma (PTC). AGR2 is a disulfide isomerase over-expressed in several human carcinomas and recently linked to endoplasmic reticulum (ER) stress. Here, we analyzed the expression of AGR2 in PTC and its functional role. Expression of AGR2 was studied by immunohistochemistry and real time PCR in normal thyroids and in PTC samples. The function of AGR2 was studied by knockdown in PTC cells and by ectopic expression in non-transformed thyroid cells. The role of AGR2 in the ER stress was analyzed upon treatment of cells, expressing or not AGR2, with Bortezomib and analyzing by Western blot the expression levels of GADD153. PTC over-expressed AGR2 at mRNA and protein levels. Knockdown of AGR2 in PTC cells induced apoptosis and decreased migration and invasion. Ectopic expression of AGR2 in non-transformed human thyroid cells increased migration and invasion and
Solid pseudopapillary tumors (SPTs) are unusual neoplasms that mostly occur in the pancreas, and predominantly affect young women. As a low-grade malignant neoplasm of the exocrine pancreas, they occasionally metastasize, usually to the liver or peritoneum. It has been reported that ,1% of SPTs are primary extrapancreatic SPTs. In the present study, we present two rare, but conspicuous extrapancreatic SPTs. Both occurred in young women, and showed good prognoses following surgery. One was a recurrent SPT of the pancreas that metastasized to the ovary, and the other was a distinct primary neoplasm that arose in the retroperitoneal area. The pathological features of the two tumors, including solid and pseudopapillary growth patterns with pale or eosinophilic cytoplasm, were characteristic of SPTs of the pancreas. However, in the case of the metastatic ovarian tumor, focal necrosis and an increased nuclear-to-cytoplasmic ratio were observed. The presence of positive nuclear-cytoplasmic β-catenin, ...
Tumor invasiveness is directly related to the ability of tumor cells to migrate and invade surrounding tissues, usually degrading extracellular matrix. Despite significant progress in the knowledge about migration and invasion, there is much more to elucidate about their regulatory mechanisms, especially in cancer cells. MicroRNAs (miRs) were recently described as important regulators of migration. Differential expression of miRs in cancer is frequently associated with progression, invasion and metastasis. In papillary thyroid carcinoma (PTC), miR-146b-5p is highly expressed and positively correlated to the degree of malignancy. This study aimed to investigate the role of miR-146b-5p on the migratory and invasive behaviors of thyroid cells, using a non tumor rat thyroid follicular cell line (PCCl3) transfected with the miR-146b-5p genomic region, and two PTC cell lines (TPC-1 and BCPAP, bearing distinct oncogenic backgrounds), which express high levels of miR-146b-5p, after miR-146b inhibition by
Papillary Thyroid Cancer Treatment cost in India starts from USD . Find affordable packages, best specialists, hospitals and patient experiences for Papillary Thyroid Cancer Treatment in India through Vaidam.
Aims: Metastatic nodes on power Doppler sonography tend to demonstrate high intranodal resistance and abnormal distribution of vascularity within a node. However, in our experience metastatic nodes from papillary carcinoma of the thyroid frequently demonstrate low intranodal resistance and some do not demonstrate the presence of any abnormal vascularity within. We were therefore interested to document these features. Materials and Methods: The grey scale and power Doppler sonograms of 21 metastatic nodes from papillary carcinoma of the thyroid were evaluated. The intranodal distribution of vessels and the intranodal vascular resistance of vessels was assessed and compared with the reported features of metastatic nodes from other head and neck primaries. Results: A majority (17/20, 85%) of metastatic nodes from papillary carcinoma of the thyroid had a maximum resistance index (RI) and pulsatility index (PI) , 0.8 and 1.6, respectively. A majority of the nodes (16/21, 76%) demonstrated abnormal ...
Solid pseudopapillary tumor of the pancreas (SPTP) is a rare pancreatic tumor. Rarely does the tumor have a multicentric location. We report this unusual case of a 24-year-old woman who had 2 large synchronous SPTPs detected incidentally by routine p
... , Authors: Jean-Loup Huret. Published in: Atlas Genet Cytogenet Oncol Haematol.
Papillary thyroid cancer (PTC) is the most common tumor subtype of thyroid cancer. However, not all PTCs are responsive to current surgical and radioiodine treatment. The well-established clinical prognostic factors include tumor size, lymph node/distal metastasis, and extrathyroidal invasion. The RET/PTC-RAS-BRAF linear molecular signaling cascade is known to mediate PTC pathogenesis. However, whether presence of BRAF mutation, the most common genetic alteration in PTC, can affect PTC behavior and prognosis is controversial. MicroRNAs (miRNAs) have been labeled as promising molecular prognostic markers in several tumor types. Our recent studies demonstrated that microRNA-146b (miR-146b) deregulation is associated with PTC aggressiveness and prognosis. Here we summarize the current knowledge related to the functional roles, regulated target genes, and clinical applications of miR-146b in PTC and discuss how these studies provide insights into the key role of miR-146b as an oncogenic regulator promoting
Yim JH , Kim WB , Kim EY , Kim WG , Kim TY , Ryu JS , Gong G , Hong SJ , Shong YK. J Clin Endocrinol Metab April, 2011. The primary treatment of locoregionally recurrent/persistent papillary thyroid cancer (PTC) is surgical removal by reoperation. This study evaluated the efficacy of the first reoperation for loco-regionally recurrent/persistent papillary thyroid carcinoma and the usefulness of stimulated TG for evaluating efficacy of reoperation. A retrospective observational cohort study was done in a tertiary referral hospital. A total of 83 patients, who underwent initial total thyroidectomy and nodal dissection with radioactive iodine remnant ablation, received reoperation for loco-regionally recurrent/persistent PTC and were included in this study. Stimulated TG levels were assessed before and after reoperation. We assessed biochemical remission (stimulated TG,1 ng/ml) after reoperation and evaluated second clinical recurrence-free survival rate according to stimulated TG value. There was ...
Nucleotides are increasingly recognized as non-redundant extracellular signals for chemotaxis, cell growth and cytokine release. Effects of extracellular nucleotides are mediated by P2 receptors, among which the P2X7 subtype is attracting increasing attention for its involvement in apoptosis, cell growth and cytokine release. Recent studies showed that P2X7 is overexpressed in chronic lymphocytic leukemia, breast and prostate cancer. The aim of the present study was to better understand the clinical significance of P2X7 receptor expression in normal and cancer human thyroid tissues. P2X7 receptor message and protein expression and functional activity were tested in two cell lines (FB1 and FB2) established from either anaplastic and papillary primary thyroid cancer and in several histological samples of human papillary cancer. We show here that human thyroid papillary carcinoma, whether of the classical or follicular variant, express the P2X7 receptor (P2X7R) to a much higher level than normal ...
Summary Global Markets Directs, Papillary Thyroid Cancer - Pipeline Review, H1 2016, provides an overview of the Papillary Thyroid Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Papillary Thyroid Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA
TY - JOUR. T1 - Outcome predictors and impact of central node dissection and radiometabolic treatments in papillary thyroid cancers ≤2 cm. AU - Perrino, Michela. AU - Vannucchi, Guia. AU - Vicentini, Leonardo. AU - Cantoni, Gianmaria. AU - Dazzi, Davide. AU - Colombo, Carla. AU - Rodari, Marcello. AU - Chiti, Arturo. AU - Beck-Peccoz, Paolo. AU - Fugazzola, Laura. PY - 2009. Y1 - 2009. N2 - The incidence of papillary thyroid cancer (PTC) is rapidly growing, the recorded increase being mainly related to tumors ≤2 cm. The re-classification of tumors ,1 and ≤2 cm limited to the thyroid from the T2 to the T1 category triggered some concerns about their best management. In order to identify possible predictors of disease outcome, several clinico-pathological features were analyzed by uni- and multivariate analyses in a retrospective consecutive series of 251 PTCs ≤2 cm. Moreover, since 37% of cases were submitted to prophylactic central compartment node dissection (CLND, VI-VII levels) and ...
Multiple studies have shown that papillary microcarcinomas are very low risk and are unlikely to grow and/or spread. As such, there is significant interest in confirming whether or not thyroid surgery can be avoided for at least some people diagnosed with papillary microcarcinoma. The purpose of the study is to provide better understanding of the risk of cancer growth and spread for patients diagnosed with papillary thyroid microcarcinoma to determine whether or not thyroid surgery is needed for such patients. ...
immune Uncategorized Dovitinib Dilactic acid, Rabbit Polyclonal to CEBPD/E Papillary thyroid carcinomas (PTCs) occasionally form multiple tumor foci in various sites of the same thyroid gland. demonstrated a concordant inactivation design Dovitinib Dilactic acid from the X-chromosome. AS-PCR indicated that mutational position between your tumor foci was discordant in three (25%) and concordant in nine (75%) of 12 obtainable situations. Once the total outcomes of the two molecular analyses had been mixed, 28.6% from the cases were discordant in X-chromosome inactivation design and/or mutation, recommending multicentric origin. A number of the remaining concordant situations could be of multicentric origins also. These total outcomes support a hypothesis that multicentric incident in multiple PTCs could be common, possibly higher than 30%. Even though specific system of multicentric incident is normally unclear still, our findings donate to the understanding the histogenesis of papillary thyroid ...
eng] INTRODUCTION: Proliferation and apoptosis are opposing processes by which the cell numbers are kept in a delicate balance, essential for tissue homeostasis, whereas uncontrolled growth of cells is a hallmark of cancer. Papillary thyroid cancer (PTC) is the commonest type of thyroid cancer, with some PTC following an indolent course, whereas the other ones are more aggressive. AIM: To evaluate respective contribution of proliferation and apoptosis in the tumorigenesis of PTC by automated analysis. MATERIALS AND METHODS: We investigated the immunolabeling of phosphorylated histone H3 (pHH3), cyclin D1, active caspase-3, and bcl-2 in thirteen cases each of metastatic PTC, follicular variant of PTC (FVPTC), papillary microcarcinoma (PMC) and well differentiated tumor of uncertain malignant potential (WDT-UMP). FVPTC cases comprised seven encapsulated and six unencapsulated cases. RESULTS: Proliferation, as assessed by pHH3 and cyclin D1 immunolabeling, was increased in all PTC variants, ...
The main nonmedullary form of thyroid cancer is papillary thyroid carcinoma (PTC) that accounts for 80-90% of all thyroid malignancies. Only 3-10% of PTC
Papillary carcinoma (PTC) is the most common form of well-differentiated thyroid cancer, and the most common form of thyroid cancer to result from exposure to radiation. Papillary carcinoma appears as an irregular solid or cystic mass or nodule in a normal thyroid parenchyma.
Unusual presentation of papillary thyroid carcinoma: about two cases.: The papillary carcinoma is the most common cancer of thyroid but its presentation may be
Background: Inactivation of p16 by methylation of CpG islands is a frequent early event in human cancers, including papillary thyroid carcinoma (PTC). This study was to observe the methylation status of the p16 gene in papillary thyroid carcinoma (PTC) and its correlation with clinical parameters.. Methods: Methylation-specific PCR (MSP) was used to analyze the methylation status of the p16 gene in 74 PTCs and 21 adjacent normal thyroid tissues.. Results: Hypermethylation of p16 gene was observed in 27.0% (20/74) of PTC. None of the normal thyroid tissues was methylated, when compared to the PTCs (p < 0.05). There was no marked relationship between the methylation of p16 gene and the patients′ age, gender, size of cancer, histological subtypes and occurrence of recurrent disease (p > 0.05). The methylation of p16 gene was positively associated with metastasis, a high AMES (age, metastasis to distant sites, extrathyroidal invasion, size) risk group (p < 0.05) and advanced pathological tumor ...
A Germline CHEK2 Mutation in a Family with Papillary Thyroid Cancer. Thyroid. 2020 Feb 11;: Authors: Zhao Y, Yu T, Chen L, Xie D, Wang F, Fu L, Cheng C, Li Y, Zhu X, Miao G Abstract Approximately 5% of all cases of PTC are inherited. However, the susceptibility gene(s) for nonsyndromic familial papillary thyroid carcinoma (FPTC) remain unclear. We performed whole genome sequen...
These images are intended for educational purposes and may be freely used for such as long as the Papanicolaou Society and the Bethesda System for Reporting Thyroid Cytopathology is credited ...
Classical papillary thyroid microcarcinoma (PTMC) is a variant of papillary thyroid carcinoma (PTC) known to have excellent prognosis. It has a mortality of 0.3%, even in the presence of distance metastasis. The latest American Thyroid Association guidelines state that although lobectomy is acceptable, active surveillance can be considered in the appropriate setting. We present the case of a 37-year-old female with a history of PTMC who underwent surgical management consisting of a total thyroidectomy. Although she has remained disease-free, her quality of life has been greatly affected by the sequelae of this procedure. This case serves as an excellent example of how first-line surgical treatment may result more harmful than the disease itself. ...
Recently, the rearrangement of RET proto-oncogene has been reported to be the most common genetic change in papillary thyroid carcinoma (PTC). However, its prevalence has been reported variably and its relation to clinical outcome has been controversial. The characteristic nuclear features of PTC ...
I was diagnosed with Eosinophilic Esophagitis and severe food allergies in June of 07 then with thyroid papillary carcinoma in December. Now they want to do Lupus tests and possibly others. I have a lo...
We describe a case of papillary thyroid carcinoma with fibromatosis/fasciitis-like stroma (PTC-FLS) that contained the rare BRAFc.1799_1801delTGA (p.V600_K601delinsE) mutation, which has not...
Aim: The aim was to study the BRAF status by immunohistochemistry (IHC) in the variants of papillary carcinoma thyroid and compare it with the clinicopathological parameters. Materials and Methods: All the thyroid carcinomas diagnosed during the period of January 2015-June 2018 were reviewed and classified according to the WHO 2017 criteria. The demographic and clinicopathological features were noted. Microarrays were prepared on 27 cases, including classic and variants of papillary thyroid carcinoma (PTC), poorly differentiated thyroid carcinoma (PDTC), and medullary thyroid carcinoma (MTC). IHC was performed with BRAF V600E by automated staining. The BRAF status was correlated with known prognostic markers. Results: There were 23 PTC, 3 PDTC, and one MTC. The PTC included seven classic, three solid, two each of microcarcinoma, infiltrative and encapsulated follicular variant, tall-cell variant (TCV), oncocytic and one each of diffuse sclerosing, nodular fasciitis-like stroma, and Warthin-like ...
A 50 year old female admitted to R L jalappa Hospital, kolar, presented with synchronous primary tumours of the thyroid and breast. Pathological examination of a tissue sample following biopsy identified papillary carcinoma of the thyroid and invasive ductal carcinoma of the breast to provide a definitive diagnosis of synchronous primary tumors. The patient was healthy prior to diagnosis and the family history was non contributory. Upon admission, the size of the primary tumour biopsied, pathological diagnosis was an invasive carcinoma of the breast. A tumor measuring 3.0x2.5x2.0 cm was identified in the right side of the thyroid lobe, however, no further abnormalities were identified. Preoperative imaging included an ultrasound of the neck, which revealed a hypoechoic heterogeneity in the right lobe of the thyroid (size, 3.2x1.5 cm) exhibiting punc¬tate calcification. The patient was negative for clinical neck lymph node metastasis. A general physical examination did not indicate any ...
Introduction: Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy, with a steadily increasing incidence in the last few decades worldwide. Studies revealed the predisposition to PTC by the heterozygous state of rs2910164 within the precursor of microRNA146a. Interestingly, on the same chromosome, 40Kb separate the pre-miR-146a from the pituitary tumour transforming gene (PTTG1), a proto-oncogene involved in thyroid carcinomas. A genome-wide study revealed an association of the genomic region encompassing pre-miR-146a and PTTG1 gene with systemic lupus erythematosus. In this study, we analyzed, with a case control design, the genetic association between PTC and pre-miR-146a rs2910164 as well as PTTG1 (rs1862391A/C and rs2910201C/T).. Methods: Two hundred and six healthy controls (30 78 of age) and 307 PTC patients (30 74 of age) were enrolled. The diagnosis of PTC was histological at surgery. Thyroid sonography was performed in controls to exclude nodules. SNP genotyping of ...
These images are intended for educational purposes and may be freely used for such as long as the Papanicolaou Society and the Bethesda System for Reporting Thyroid Cytopathology is credited ...
Ectopic lingual thyroid tissue is an uncommon developmental anomaly. Tumours of identical pathological characteristics as those arising in the eutopic thyroid tissue, may be present in ectopic locations. There are very few cases of malignant tumours reported in the literature. Here we report a rewiew of this pathology and we describe a case of a papillary carcinoma of the base of the tongue, located in ectopic lingual thyroid tissue, in a 66 year-old white man, complaining of dysphagia and oral bleeding. Surgical treatment was carried out, consisting of radical resection of the right hemineck, tumour resection, right hemyglosectomy and total thyroidectomy. Postoperative treatment with 131I and substitutive thyroid hormonal therapy was prescribed.. ...
Papillary thyroid cancer, thyroid nodule surgery, thyroid cancer surgery, parathyroid gland disorders, parathyroid surgery. Call 1300 113 310 Sydney.
TY - JOUR. T1 - Re. T2 - "long-Term Outcomes of Patients with Papillary Thyroid Cancer Undergoing Remnant Ablation with 30 Millicurie Radioiodine" by Mujammami et al. (Thyroid 2016;26:951-958): Patient Cohort Definition Makes No Sense. AU - Tulchinsky, Mark. AU - Avram, Anca M.. PY - 2017/4/1. Y1 - 2017/4/1. UR - http://www.scopus.com/inward/record.url?scp=85017124971&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=85017124971&partnerID=8YFLogxK. U2 - 10.1089/thy.2016.0455. DO - 10.1089/thy.2016.0455. M3 - Letter. C2 - 27750025. AN - SCOPUS:85017124971. VL - 27. SP - 591. JO - Thyroid. JF - Thyroid. SN - 1050-7256. IS - 4. ER - ...
An individual with 2 first-degree relatives who have or have had non-medullary thyroid cancer or a documented diagnosis of non-medullary thyroid cancer and one living relative with documented non-medullary thyroid cancer. (Note: as this is a familial study, subjects do not need to present with the disease.). OR. Any member of an affected family. (Note: for this study, an affected family is defined as a family having 2 or more 1st degree relatives with a documented diagnosis of FNMTC.). ...
Latest news and research breakthroughs on Papillary Thyroid Cancer. Last updated on Feb 14, 2018 with over 57 News and research items available on the subject. Freely Download - Papillary Thyroid Cancer News Widget
Although age 45 is used to establish staging in well-differentiated papillary thyroid cancer using the American Joint Committee on Cancer and the International Union Against Cancer TNM Classification of Malignant Tumors (TNM) staging system, a new study presented at the 82nd Annual Meeting of the American Thyroid Association (ATA) in Québec City, Québec, Canada, suggests that > 65 may be a more accurate age marker for prognosis.
Several recently published papers have introduced contradicting findings on the usefulness of BRAF status for predicting the presence of aggressive papillary thyroid cancer.
Five-year relative survival rates are near 100 percent for individuals with stage 1 and 2 papillary thyroid cancer, according to the American Cancer Society. The five-year relative survival rate for...
Lee, J. C., Zhao, J. T., Clifton-Bligh, R. J., Gill, A., Gundara, J. S., Ip, J. C., Glover, A., Sywak, M. S., Delbridge, L. W., Robinson, B. G. and Sidhu, S. B. (2013), MicroRNA-222 and MicroRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. Cancer, 119: 4358-4365. doi: 10.1002/cncr.28254 ...
The big questions are: 1. For a papillary thyroid carcinoma sized 23 mm and removed in a total thyroidectomy, is it really necessary to have RAI treatment? A metastasised lymph node was removed also...
Mutations in certain cancer-associated genes are frequently found in papillary thyroid cancer. In particular, BRAF V600E mutations are found in up to 80% of cases of papillary thyroid cancer. This study aimed to determine the relationship between the BRAF V600E mutation status and clinical outcome of papillary thyroid cancer.
(a) Curettage material with papillary carcinoma (hematoxylin and eosin, ×100), (b) Cut surface of the hysterectomy specimen with friable tissue in the endocerv
Top 10 cancers for 11759532_at (Homo sapiens, Affymetrix Probeset): Langerhans-cell histiocytosis, multifocal and multisystemic, other neoplasms of lymphoid, hematopoietic and related tissue, Langerhans-cell histiocytosis, multifocal and unisystemic, Langerhans-cell histiocytosis, unifocal, breast, invasive micropapillary carcinoma, skin, squamous cell carcinoma, NOS, brain, small cell glioblastoma, brain, oligodendroastrocytoma, cutaneous T-cell lymphoma, NOS, kidney, adenocarcinoma, NOS, metastatic
15 Dec 2017. A 10-year study of more than 1,200 patients with low-risk papillary microcarcinoma (PMC) of the thyroid led researchers to conclude that close and continuous monitoring is an acceptable first-line approach to patient management instead of immediate surgery to remove the tumour.. The article entitled Insights into the Management of Papillary Microcarcinoma of the Thyroid is part of a special section on Japanese Research led by Guest Editor Yoshiharu Murata, Nagoya University, Japan, in the January 2018 issue of Thyroid, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers and the official journal of the American Thyroid Association (ATA).. The article is available free on the Thyroid website.. Coauthors Akira Miyauchi, Yasuhiro Ito, and Hitomi Oda, Kuma Hospital, Kobe, Japan, report that in only 8% of patients with PMC evaluated during the study period did the tumour increase in size by 3 mm or more, and only 3.8% of patients had a new metastasis.. PMCs were least likely ...
There is an increased risk of thyroid cancer associated with lower-than-normal thyroid hormone levels, a finding that could have a major impact on patients fighting the disease. The Yale-led study, published in American Association for Cancer Research journal examined the effect of Thyroid Stimulating Hormone (TSH) on the development of human papillary thyroid cancer (PTC). […]. ...
Malignant tumors of the thyroid gland vary considerably in aggressiveness, ranging from a well-differentiated, clinically indolent, to an undifferentiated, often lethal phenotype. Undifferentiated (anaplastic) thyroid tumors are supposed to be derived, through a process of progression, from previously differentiated neoplasms. A common genetic alteration in thyroid tumors is the rearrangement of the tyrosine kinase-encoding RET proto-oncogene, leading to the generation of chimeric RET/PTC oncogenes. To define the characteristics of the thyroid tumor subset with RET rearrangements, we have investigated its activation by a combined immunohistochemistry and reverse transcription-PCR approach in a series of 316 well-characterized thyroid tumors representative of the main diagnostic groups. RET activation was detected in 81 of 201 (40.3%) papillary carcinomas. It correlated with tumors exhibiting the "classic" morphological features of papillary cancer or with the microcarcinoma subtype (P = 0.017). ...
Prognosis of thyroid cancer that has spread to lungs - What is the prognosis for papillary thyroid cancer that spread to the lungs? I read it is normally not more than 5 years survival rate? Is that true? Variable. The rate of survival in patients with papillary thyroid cancer with distant metastases is variable. Considering patients with small lung metastases but no other spread outside of the neck, the 10-year survival rate is roughly 30 to 50 percent. Higher survival rates have been reported in patients whose pulmonary mets were detected only by radioiodine imaging. Being over 80 hurts your prognosis.
Clinicians may be able to utilize this information as an effective preoperative tool to stratify risk and determine an initial surgical approach for patients with PTC.
lncRNA DGCR5 plays a role as tumor suppressor in certain types of cancer, including lung cancer, but serves as an oncogene in other types of cancer, including papillary thyroid carcinoma and liver cancer (11,12,16). The present study revealed the tumor suppressive role of DGCR5 in CRC and demonstrated that DGCR5 may inhibit the proliferation of CRC cells by downregulating miR-21, an oncogenic miRNA in CRC (13).. DGCR5 has opposite functions in different types of cancer. DGCR5 was upregulated during the development of lung cancer, and DGCR5 overexpression inhibited hsa-mir-22-3p to promote cancer development (11). By contrast, DGCR5 inhibits miR-2861 to serve a tumor suppressive role in papillary thyroid carcinoma (12). The present study revealed that that DGCR5 was downregulated in CRC tissues compared with healthy adjacent non-cancer in patients with CRC patients. Additionally, overexpression of DGCR5 decreased the proliferation of CRC cells in vitro. Therefore, the results obtained in the ...
Though sample size was small, we found several deregulated miRNAs having racial differences. The differential expression of miRNAs suggest that these miRNAs and their target genes could be useful to gain further mechanistic insight of PTC and their clinical implications, including miRNA replacement …
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
PubMed comprises more than 30 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.
Researchers at Thomas Jefferson University Hospital have shown that age 45 is no longer a useful predictor of negative outcomes in the staging of papillary thyroid cancer patients. Their findings were among the most impactful abstracts recently presented at the American Thyroid Association annual meeting in Quebec City, Quebec, Canada.
Coquia, Stephanie F.; Chu, Linda C.; Hamper, Ulrike M. (2014). "The Role of Sonography in Thyroid Cancer". Radiologic Clinics of North America. 52 (6): 1283-1294. doi:10.1016/j.rcl.2014.07.007. ISSN 0033-8389 ...
Onset between Second and Sixth Decade Symptom Checker: Possible causes include Familial Papillary Thyroid Carcinoma with Papillary Renal Cell Carcinoma. Check the full list of possible causes and conditions now! Talk to our Chatbot to narrow down your search.
Recurrence of DTC has been previously reported to be dependent on tumor characteristics, the tumor size, the presence of lymph node metastasis, the presence of extra thyroid invasion, the presence of distant metastasis, oncogenes such as B-RAF proto-oncogene, advanced age and male sex.
This website uses cookies to help you receive a better online experience. By using this website, you are agreeing to the use of cookies as explained in our privacy policy ...
After finding out that I was definitely going to need a biopsy, I wasnt nervous about the results, I was more worried about the actual process... Really, who likes needles? Especially one that needs to go into your neck. As the day came closer, I became more nervous about the possibilities for the results. I…
If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team ...
Background Serum miRNAs profiles between papillary thyroid carcinoma (PTC) individuals with non-131I and 131I-avid lung metastases are differentially expressed. receptor beta (RARB) 3-UTR. miR-106a-RARB promoted viability of thyroid cancers cells by regulating MEKK2-ERK5 and MEKK2-ERK1/2 pathway. miR-106a-RARB inhibited apoptosis of thyroid cancers cells by regulating ASK1-p38 pathway. Furthermore, miR-106a-RARB could regulate the appearance of sodium […]. ...
Somatic rearrangement of the tyrosine kinase receptor RET is restricted to papillary thyroid carcinoma (PTC). The prevalence of RET/PTC1, RET/PTC2, and RET/PTC3 has been found to vary between 0% and 20% in most series of sporadic (nonradiation-induced) PTCs analyzed by type-specific reverse transcription-polymerase chain reaction (RT-PCR) alone. However, high prevalence reported from Taiwan (6 out of 11, 55%) indicates RET rearrangement is an important genetic lesion underlying the development of PTC in Taiwan. Because the high prevalence of RET rearrangements in Chinese patients was particularly striking, we were prompted to reexamine chimeric transcripts of RET/PTC1, RET/PTC2, and RET/PTC3 using the same experimental designs in a larger number of cases in the same population. RT-PCR was performed to amplify fusion products of RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET from frozen tissue of 105 sporadic PTCs. RT-PCR was also performed with two different primer sets for RET/PTC1, RET/PTC2, and ...
Angiogenesis, which is essential for tumor growth and progression (1) , does not involve a single pathway, but is a complex of many factors and signal transduction systems. Within this angiogenesis complex, the balance between angiogenic and antiangiogenic factors is important (33) . In the present study, we investigated the expression and distribution of TSP and CD36 in papillary thyroid carcinomas to detect the expression of two antiangiogenic factors and four angiogenic factors: VEGF, VEGF-C, Tie-2, and Ang-2. All of these factors appeared in the cytoplasm of the tumor, demonstrating production by thyroid cancer cells. It is generally recognized that cancer cells produce VEGF and VEGF-C (34 , 35) . Ang-2 is expressed in the cytoplasm of cancer cells in hepatocellular carcinoma (36) , Kaposis sarcoma (37) , and gastric carcinoma (38) . Its expression is localized in the endothelial cells of glioblastoma (39) , astrocytoma (40) , and non-small cell lung cancer (41) , but not in the cancer ...
目的:检测PRSS3-mRNA及lncRNA-PRSS3P2在甲状腺乳头状癌(papillary thyroid carcinoma,PTC)及癌旁甲状腺组织中的表达特点,探讨二者在PTC中表达的临床病理意义。方法:收集2016年7至10月本院55例PTC及癌旁甲状腺组织的新鲜手术标本,应用荧光实时定量PCR检测PRSS3-mRNA及lncRNA-PRSS3P2在PTC和癌旁组织中表达情况,并分析其与临床病理特征的相关性。结果:PRSS3-mRNA及lncRNA-PRSS3P2在PTC组织中表达均明显高于非肿瘤组织;PRSS3P2的表达与患者的年龄相关(P|0.05),而PRSS3与各种临床病理特征无明显相关性。结论:在PTC组织中,PRSS3-mRNA和lncRNA-PRSS3P2的表达均明显升高,这提示二者可能参与了PTC的发病过程;PRSS3-mRNA和lncRNA-PRSS3P2可以作为PTC的诊断标志物进行进一步研究。
18f-fdg, Carcinoma, Lymph, Lymph Nodes, Metastasis, Papillary Carcinoma, Patients, Pet, Report, Serum, Thyroglobulin, Thyroid, Thyroid Carcinoma, Thyroidectomy
Principal Investigator:FUJIHIRA Takashi, Project Period (FY):1996 - 1997, Research Category:Grant-in-Aid for Scientific Research (C), Section:一般, Research Field:内分泌・代謝学
Ali M.; Abussa A.; Hashmi H. (2007). "Papillary thyrpid carcinoma formation in a thyroglossal cyst. A case report". Libyan ... McNicoll MP, Hawkins DB, England K, Penny R, Maceri DR (1988). "Papillary carcinoma arising in a thyroglossal duct cyst". ... Thyroglossal duct cyst carcinoma[edit]. Rarely, cancer may be present in a thyroglossal duct cyst. These tumors usually arise ... Thyroglossal duct carcinoma occurs in approximately 1 to 2% of Thyroglossal cyst cases.[20] ...
who first arbitrarily coined the term "occult papillary carcinoma" in 1960, to describe papillary carcinomas ≤ 1.5 cm in ... Woolner LL, Lemmon ML, Beahrs OH, Black BM, Keating FR (1960). "Occult papillary carcinoma of the thyroid gland: a study of 140 ... Harach HR, Franssila KO, Wasenius VM (1985). "Occult papillary carcinoma of the thyroid. A "normal" finding in Finland. A ... Others Thyroid lymphoma Squamous cell thyroid carcinoma Sarcoma of thyroid The follicular and papillary types together can be ...
It was found that miR-181a and miR-181c are overexpressed in Papillary Thyroid Carcinoma tumors, sufficiently to successfully ... "The role of microRNA genes in papillary thyroid carcinoma". Proceedings of the National Academy of Sciences of the United ... It has been shown that conserved miR-181 family were upregulated in EpCAM+ AFP+ Hepatocellular carcinoma (HCC) cells and EpCAM+ ... Mir-210 has been suggested as a useful biomarker to distinguish adrenocortical carcinoma from adrenocortical adenoma. in ...
Various mutations in the MET gene are associated with papillary renal carcinoma. MET proto-oncogene (GeneID: 4233) has a total ... Foretinib has completed a phase 2 clinical trials with indications for papillary renal cell carcinoma, gastric cancer, and head ... Dharmawardana PG, Giubellino A, Bottaro DP (2004). "Hereditary papillary renal carcinoma type I". Curr. Mol. Med. 4 (8): 855-68 ... IL-2 has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of renal cell carcinoma and metastatic ...
"Entrez Gene: PRCC papillary renal cell carcinoma (translocation-associated)". Zbar B, Glenn G, Lubensky I, et al. (1995). " ... In a subset of papillary renal cell carcinomas, a t(X;1)(p11;q21) chromosome translocation has been repeatedly reported and is ... Meloni AM, Dobbs RM, Pontes JE, Sandberg AA (1993). "Translocation (X;1) in papillary renal cell carcinoma. A new cytogenetic ... 2001). "PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors". ...
... showed upregulation in papillary thyroid carcinoma. Annexin A5 is used as a non-quantitative probe to detect cells ... "Proteomic profiling of follicular and papillary thyroid tumors". European Journal of Endocrinology / European Federation of ...
It is overexpressed in some thyroid papillary carcinomas. This gene is located in a cluster of zinc finger genes at 3p21. ...
"The role of microRNA genes in papillary thyroid carcinoma". Proceedings of the National Academy of Sciences of the United ... "Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma". Proceedings of the ...
"Increased type 3 deiodinase expression in papillary thyroid carcinoma". Thyroid. 22 (9): 897-904. doi:10.1089/thy.2012.0031. ... "DLK1-DIO3 genomic imprinted microRNA cluster at 14q32.2 defines a stemlike subtype of hepatocellular carcinoma associated with ...
Follicular carcinoma tends to metastasize to lung and bone via the bloodstream. Papillary thyroid carcinoma commonly ... Thus, follicular thyroid carcinomas seem to arise by two distinct and virtually nonoverlapping molecular pathways. Belge G, ... Like follicular carcinoma, unilateral hemithyroidectomy is performed for non-invasive disease, and total thyroidectomy for ... Hurthle cell thyroid cancer is often considered a variant of follicular cell carcinoma. Hurthle cell forms are more likely than ...
Papillary thyroid carcinoma is targeted using a polyplex nanoparticle. The core consists of biodegradable poly ... In the case of ovarian clear cell carcinoma, gro-α and its receptor have been found to be overexpressed. This pro-inflammatory ... hormone peptide-conjugated nanoparticle system improves its specificity and efficacy in ovarian clear cell carcinoma in vitro ...
... a novel gene overexpressed in papillary thyroid carcinomas". Oncogene. 21 (33): 5056-68. doi:10.1038/sj.onc.1205687. PMID ...
... of papillary thyroid carcinoma, a malignant cancer. The cancer (red) is much stiffer than the healthy tissue. ...
Clear cell carcinoma: loss of 3p Papillary carcinoma: trisomy 7 and 17 Chromophobe carcinoma: hypodiploid with loss of ... Clear cell renal carcinoma: del 9p and del 14q are poor prognostic indicators. Papillary renal cell carcinoma: duplication of ... "Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma". Clinical Cancer Research. 15 ( ... Szponar A, Zubakov D, Pawlak J, Jauch A, Kovacs G (2009). "Three genetic developmental stages of papillary renal cell tumors: ...
2009). "Mutation analysis of RAP1 gene in papillary thyroid carcinomas". Endocr. J. 56 (1): 161-4. doi:10.1507/endocrj.k08e-244 ...
"Small bowel [duodenum or periampulla] carcinoma 4-12% [distal to duodenum] Rare; Pancreas Adenocarcinoma ~1%; Papillary thyroid ... Mutation of APC also occurs commonly in incident cases of colorectal carcinoma, emphasizing its importance in this form of ... Mutation of APC also occurs commonly in incident cases of colorectal carcinoma, emphasizing its importance in this form of ... "A genetic and clinical study of intestinal polyposis, a predisposing factor for carcinoma of the colon and rectum". Am J Hum ...
Kim HJ, Chung JK, Hwang do W, Lee DS, Kim S (2008). "In vivo imaging of miR-221 biogenesis in papillary thyroid carcinoma". Mol ... "In vivo imaging of functional targeting of miR-221 in papillary thyroid carcinoma". J Nucl Med. 49 (10): 1686-93. doi:10.2967/ ... both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle". Endocr Relat Cancer ... "The inhibition of the highly expressed miR-221 and miR-222 impairs the growth of prostate carcinoma xenografts in mice". PLoS ...
Corvi R, Berger N, Balczon R, Romeo G (2000). "RET/PCM-1: a novel fusion gene in papillary thyroid carcinoma". Oncogene. 19 (37 ...
Another study identified Dock10 as a protein that was overexpressed in some aggressive papillary thyroid carcinomas. GRCh38: ... February 2006). "Gene expression in poorly differentiated papillary thyroid carcinomas". Thyroid. 16 (2): 161-75. doi:10.1089/ ...
This protein has been linked to breast cancer and papillary thyroid carcinoma. C8orf48 is located on chromosome 8 (8p22) and ... C8orf48 has been found in studies regarding various types of carcinoma. Different C8orf48 expression levels have been found in ... Other studies demonstrate differential expression of Papillary Thyroid cancer and Estrogen Receptor alpha-silenced MCF7 breast ... Papillary Thyroid cancer and Estrogen Receptor alpha-silenced MCF7 breast cancer cells. GRCh38: Ensembl release 89: ...
... to be reported as possible diagnostic marker of papillary thyroid carcinoma. GRCh38: Ensembl release 89: ENSG00000197956 ... binding protein S100A6 in papillary thyroid carcinoma". Thyroid. 20 (10): 1067-76. doi:10.1089/thy.2009.0400. PMID 20629554. ...
Associated with papillary variant of renal cell carcinoma and multiple cutaneous leiomyoma. Defect is in the fumarate hydratase ... malignant carcinoma is still 50 times more likely. Approximately 50% of cases are found in the jejunum, followed by the ileum ...
high grade neuroendocrine carcinoma, ICD-O 8246/3) *z dużych komórek (ang. large cell neuroendocrine carcinoma, ICD-O 8013/3) ... Papillary adenocarcinoma of the stomach. „Gastric Cancer". 3 (1), s. 33-38, Aug 2000. PMID: 11984707. ... squamous cell carcinoma, ICD-O 8070/3). *rak z limfoidnym podścieliskiem (rdzeniasty) (ang. carcinoma with lymphoid stroma ( ... signet ring cell carcinoma and other variants; poorly cohesive carcinoma, ICD-O 8490/3) ...
Of the total, 1,251 (94%) were transitional cell carcinoma of the papillary type. "Five-year relative survival rates from ... Ureteral cancer is usually transitional cell carcinoma. Transitional cell carcinoma is "a common cause of ureter cancer and ...
Cervical lymph node metastasis is a common feature of papillary thyroid carcinoma Henri Rouvière produced an influential ... "Significance of the Extracapsular Spread of Metastatic Lymph Nodes in Papillary Thyroid Carcinoma". Clinical and Experimental ...
... are considered to be medium-strength peels and affect the skin as deep as the papillary dermis.[32] Formulations of ... squamous-cell carcinoma. *basal-cell carcinoma. *Merkel-cell carcinoma. *nevus sebaceous. *trichoepithelioma ...
What are the signs of papillary urothelial carcinoma, what are the causes, and what are the risk factors? ... What is papillary urothelial carcinoma?. Papillary urothelial carcinoma forms in the inner lining of the bladder. ... Signs of papillary urothelial carcinoma. Signs and symptoms of papillary urothelial carcinoma are similar to signs and symptoms ... Generally, people with papillary urothelial carcinoma have a high likelihood of a good outcome, as most cases of papillary ...
There are two common types: cystic (noninvasive form) and micropapillary ductal carcinoma (invasive form). Papillary br... more ... Papillary carcinoma of the breast encompasses a spectrum of histologic subtypes. ... encoded search term (What are papillary carcinomas of the breast?) and What are papillary carcinomas of the breast? What to ... Papillary carcinoma. Solid papillary growth pattern with early cribriform and well-developed thin papillary fronds. ...
Papillary carcinoma of the thyroid is the most common cancer of the thyroid gland. The thyroid gland is located inside the ... Papillary carcinoma of the thyroid is the most common cancer of the thyroid gland. The thyroid gland is located inside the ... About 85% of all thyroid cancers diagnosed in the United States are the papillary carcinoma type. It is more common in women ... The survival rate for papillary thyroid cancer is excellent. More than 90% of adults with this cancer survive at least 10 to 20 ...
I had my entire thyroid taken out a few years ago because after having a biopsy they discovered I had papillary carcinoma that ...
Figure 1: Number of papillary thyroid carcinoma (PTC) patients and percentage of papillary thyroid microcarcinoma and ... Prognosis of Multifocal Papillary Thyroid Carcinoma. Sheng-Fong Kuo,1 Shu-Fu Lin,1 Tzu-Chieh Chao,2 Chuen Hsueh,3 Kun-Ju Lin,4 ... numerous clinical reports have noted an increased incidence of both papillary thyroid carcinoma (PTC) and papillary thyroid ... J.-D. Lin, T.-C. Chao, C. Hsueh, and S.-F. Kuo, "High recurrent rate of multicentric papillary thyroid carcinoma," The Annals ...
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we describe the genomic landscape of 496 ... Integrated genomic characterization of papillary thyroid carcinoma.. Cancer Genome Atlas Research Network1. ... Genetics: The genomic landscape of papillary thyroid carcinoma. [Nat Rev Endocrinol. 2015] ... We observed a low frequency of somatic alterations (relative to other carcinomas) and extended the set of known PTC driver ...
Papillary carcinoma appears as an irregular solid or cystic mass or nodule in a normal thyroid parenchyma. ... Papillary carcinoma (PTC) is the most common form of well-differentiated thyroid cancer, and the most common form of thyroid ... encoded search term (Papillary Thyroid Carcinoma) and Papillary Thyroid Carcinoma What to Read Next on Medscape. Related ... Papillary Thyroid Carcinoma Guidelines. Updated: Feb 06, 2018 * Author: Ponnandai S Somasundar, MD, MPH, FACS; Chief Editor: ...
... Ihsen Slim,1 Aida Mhiri,1 Imène Meddeb,1 Aida Goucha,2 Saïd ... "Malar Bone Metastasis Revealing a Papillary Thyroid Carcinoma," Case Reports in Otolaryngology, vol. 2012, Article ID 795686, 4 ...
Papillary thyroid carcinoma is the most common form of differentiated thyroid carcinoma. It is generally confined to the neck ... Malar Bone Metastasis Revealing a Papillary Thyroid Carcinoma. Ihsen Slim,1 Aida Mhiri,1 Imène Meddeb,1 Aida Goucha,2 Saïd ... Papillary thyroid carcinoma (PTC) is the most common form of thyroid malignancy with a good prognosis, since it is generally ... Follicular thyroid carcinoma is known to metastasize via the bloodstream; such a pattern of spread is rare in papillary thyroid ...
... Deanne Soares, Nariman Ahmadi, Oana Crainic, and John ... We report a case of tumour seeding caused by percutaneous biopsy of a papillary renal cell carcinoma detected on pathological ... Figure 5: High power view of the papillary renal cell carcinoma seeding along the previous percutaneous biopsy tract. ... Histologically this was a type 1 papillary renal cell carcinoma. During examination of the fat overlying the tumour, viable ...
Care guide for Papillary Thyroid Carcinoma (Aftercare Instructions). Includes: possible causes, signs and symptoms, standard ... Papillary thyroid carcinoma is also called PTC. It is a kind of tumor (abnormal growth) found in your thyroid gland. The ... Learn more about Papillary Thyroid Carcinoma (Aftercare Instructions). Associated drugs. *Thyroid Disease ...
Papillary urothelial neoplasm with moderate to high-grade cytology.. *Includes some former 1973 WHO TCC grade 2 and all grade 3 ... Urothelial Carcinoma of the Prostate * Carcinoma With Squamous Differentiation * Basal Cell Carcinoma (Adenoid Cystic Carcinoma ...
Much attention has been generated regarding the topic of thyroid neoplasia and papillary thyroid carcinoma. This attention can ... Malignant: (a) Papillary thyroid carcinoma, (b) poorly differentiated carcinoma, (c) medullary thyroid carcinoma, (d) ... Suspicious for papillary carcinoma, (b) suspicious for medullary carcinoma, (c) suspicious for metastatic carcinoma, (d) ... Thyroid, Papillary Carcinoma, Early Workup. Updated: Apr 06, 2016 * Author: Eric J Lentsch, MD; Chief Editor: Arlen D Meyers, ...
It has emerged that of the 38,000 Americans diagnosed with renal cell carcinoma (RCC) each year, approximately 20 percent have ... "We really need to investigate papillary renal cell carcinoma separately from clear-cell renal cell carcinoma and aggressively ... Renal Cell Carcinoma. Renal cell carcinoma is kidney cancer that affects the lining of the kidney tubules. The initial stages ... New findings shows that a non-clear cell form of kidney cancer known as papillary RCC, which accounts for 12 percent of all RCC ...
Clear cell papillary renal cell carcinoma, abbreviated CCPRCC and also known as clear cell tubulopapillary renal cell carcinoma ... is a rare subtype of renal cell carcinoma (RCC) that has microscopic morphologic features of papillary renal cell carcinoma and ... 2011). "Case Report: Clear Cell Papillary Renal Cell Carcinoma in the Bilateral Native Kidneys after 2 Years of Renal ... September 2011). "Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the ...
Antitumor actions of cytokines on new human papillary thyroid carcinoma cell lines.. Ohta K1, Pang XP, Berg L, Hershman JM. ... To investigate the in vitro effects of cytokines on the growth of human papillary thyroid carcinoma (PTC) cells, we established ... anaplastic thyroid carcinoma cell line). These cells were treated with various concentrations of tumor necrosis factor-alpha ( ...
Papillary serous carcinoma of ovarian type of the testis with borderline differentiation.. Guarch R, Rivas A, Puras A, Pesce C. ...
... patients with papillary thyroid carcinoma (PTC) have an excellent postoperative prognosis. Those with cricoid and/or tracheal ... Papillary Thyroid Carcinoma Recurrent Laryngeal Nerve Aerodigestive Tract Total Laryngectomy Papillary Thyroid Carcinoma ... Locally invasive papillary thyroid carcinoma: 1940-1990. Head Neck. 1994;16:165-72.CrossRefPubMedGoogle Scholar ... Local prognosis of patients with papillary thyroid carcinoma who were intra-operatively diagnosed as having minimal invasion of ...
The optimal management of patients with stage I uterine papillary serous carcinoma (UPSC) is unclear. We sought to determine ... OBJECTIVE: The optimal management of patients with stage I uterine papillary serous carcinoma (UPSC) is unclear. We sought to ... Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecologic Oncology, 105(3), 677-682. DOI: 10.1016/j.ygyno. ...
Type 1 papillary renal cell carcinoma Type 2 papillary renal cell carcinoma Clear cell papillary renal cell carcinoma. ... Papillary renal cell carcinomas are subtypes of renal cell carcinoma (RCC). ...
... to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol ... BRAF mutation in papillary thyroid carcinoma. JNCI Cancer Spectrum 2003;95:625-7. [ Links ]. 50. Kim KH, Kang DW, Kim SH, Seong ... Anomalous papillary carcinoma of the thyroid. Cancer 1983;51:1462-7. [ Links ]. 12. Roque L, Nunes VM, Ribeiro C, Martins C, ... Oncogene profile of papillary thyroid carcinoma. Surgery 1999;125:46-52. [ Links ]. 71. Zhu Z, Gandhi M, Nikiforova MN, Fischer ...
Thyroid cancer - papillary carcinoma. Definition. Papillary carcinoma of the thyroid is the most common cancer of the thyroid ... Papillary carcinoma of the thyroid. Causes. About 80% of all thyroid cancers diagnosed in the United States are the papillary ... The survival rate for papillary thyroid cancer is excellent. More than 95% of adults with this cancer survive at least 10 years ... NCCN clinical practice guidelines in oncology: Thyroid carcinoma. Version 2.2015. www.nccn.org/professionals/physician_gls/PDF/ ...
Abcam provides specific protocols for Anti-Papillary renal cell carcinoma antibody (ab114998) : Immunoprecipitation protocols, ...
References for Abcams Anti-Papillary renal cell carcinoma antibody (ab117797). Please let us know if you have used this ...
It is an uncommon variant of papillary thyroid carcinoma with about 80 cases reported in the literature and it is often ... We report a rare case of Warthin tumor-like papillary thyroid carcinoma confi rmed by histology. ... The epidemiologic features of this variant of papillary thyroid carcinoma are similar to the classic papillary carcinoma. A 58- ... This tumor can be easily mistaken for Hurthle cell carcinoma and tall cell variant of papillary carcinoma both by FNA and ...
  • Histologic examination of collecting duct carcinoma demonstrates an infiltrative lesion with tubulopapillary, irregular channels lined by high grade hobnail cells with marked desmoplastic response and brisk neutrophilic infiltrate. (wikipedia.org)
more